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Abstract 
Resolvins are endogenous anti-inflammatory I pro-resolving lipid 
mediators derived from omega-3 fatty acids. Resolvin E1 (RvE1) reverses 
periodontitis and promotes regeneration of alveolar bone in vivo. The goal of this 
project was to determine the mechanism of RvE1 impact on bone formation. 
RvE1 significantly enhanced bone formation relative to a vehicle control in a 
mouse craniotomy model of bone healing. Since RvE1 is reported to act through 
receptors expressed by cells of the innate immune system, the initial hypothesis 
tested was that RvE1 actions are mediated through bone macrophages. The 
hypothesis was rejected , as no impact of RvE1 on macrophage mediated bone 
formation was demonstrable. The alternative hypothesis was that RvE1 acts 
directly on osteoblasts. Using mouse neonatal osteoblasts, calcification of 
osteoblast cultures was demonstrated. Osteoblasts express the RvE1 receptor, 
ChemR23, at the mRNA and protein level. Examination of intracellular signaling 
v 
by RvE1 demonstrated increased phosphorylation of rpS6 through the AKT-
mTOR pathway. The specificity of RvE1 signaling through ChemR23 was 
demonstrated with ChemR23 specific blocking antibody that abrogated the 
phosphorylation of rpS6. Rapamycin, an inhibitor of mTOR, also blocked rpS6 . 
phosphorylation. 
To examine the mechanism of RvE1 treated osteoblast enhanced bone 
formation , secretion of bone specific proteins by osteoblasts after pro-
inflammatory stimulation (IL-6) was examined with a focus on the osteoprotegerin 
(OPG) and receptor activator of NF-KB ligand (RANKL) axis, which regulates 
osteoclast differentiation. Secretion of RANKL and OPG by mouse neonatal 
osteoblasts stimulated with IL-6 and treated with RvE1 was measured by ELISA. 
IL-6 stimulation did not impact RANKL levels but decreased OPG production , 
thereby changing the RANKL!OPG to favor osteoclast activation and bone 
resorption. RvE1 blocked OPG changes, however, maintaining a RANKLIOPG 
more favorable to bone formation. 
In conclusion , RvE1 has anabolic actions in a mouse model of bone 
healing mediated through RANKL/OPG. RvE1 signals the receptor ChemR23 on 
the osteoblast surface through the mTOR pathway and phosphorylation of rpS6. 
Functionally, RvE1 shifts the balance between OPG and RANKL to favor bone 
formation . Mediators of innate immunity thus also directly regulate bone cells. 
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1 Introduction and Review of the Literature 
Bone is a tissue undergoing perpetual remodeling, a physiological process 
mediated by metabolic and mechanical stimuli. Bone repair occurs after 
traumas, such as open fractures, fragility fractures, and placement of orthopedic 
and dental implants. Local osteoprogenitor cells differentiate into osteoblasts, 
which are responsible for matrix and mineral production as well as for stimulation 
of bone resorption by recruitment of osteoclasts from hematopoietic precursors. 
Many systemic hormones participate in the regulation of bone function, including: 
parathyroid hormone (PTH), 1 ,25-dihydroxyvitamin 0 3, glucocorticoids, and 
estrogen. Local factors also regulate bone function, including: fibroblast growth 
factor (FGF), bone morphogenetic proteins (BMPs), insulin-like growth factor 
(IGF) , platelet-derived growth factor (PDGF) and cytokines such as tumor 
necrosis factor (TNF)-a and interleukins (IL)-1 and 6. 
Bone homeostasis is susceptible to disruption in pathological conditions. 
Inflammation is now known to play a major role in bone pathology. The new field 
of osteoimmunology is defined as the study of the interaction between the 
immune system and bone function. In inflammatory conditions of the bone, 
initiated by trauma, autoimmune disease, or infection, leukocytes within the 
inflamed tissue produce a myriad of chemical mediators, including eicosanoids, 
which not only act on other immune cells but also act directly upon bone tissue. 
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It is becoming clear that there is a reciprocal interaction between bone cells and 
the immune system, particularly innate immunity. 
The way we understand the inflammatory response was changed with the 
seminal discovery by Dr. Charles Serhan , namely that resolution of inflammation 
is an active ligand- and receptor-mediated process regulated by specialized lipid 
mediators (SLM). SLM, include lipoxins, resolvins, protectins and maresins, 
which target specific receptors on inflammatory cells; hence the concept of 
"active" resolution. These ligands prospectively signal cells along new pathways; 
they do not act by inhibition of enzyme pathways or function as receptor 
antagonists. 
Prior observations in the Van Dyke laboratory suggest that there is 
potential for the use of resolvins in the pharmacological treatment of periodontal 
disease. In a rabbit model of periodontal disease, resolvin E1 (RvE1) prevented 
bone resorption and induced regeneration (1). Further observations in the 
Gyurko laboratory suggest that RvE1 has direct actions on osteoclasts. RvE1 
reduced osteoclast differentiation and resorption pit formation (2) . 
Bone tissue function is characterized by coupling between bone resorption 
and formation; functions fulfilled by osteoclasts and osteoblasts, respectively. In 
addition to direct actions of RvE1 on osteoclasts (2} , unpublished observations 
by the Gyurko and Van Dyke laboratories suggest induction of new bone 
formation by osteoblasts in bone treated with RvE 1. The action of RvE 1 on 
osteoblasts has not been previously investigated. The goal of the studies 
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reported in this dissertation was to characterize the direct and indirect actions of 
RvE1 on bone formation, with a focus on osteoblasts. 
1.1 Acute inflammation 
Inflammation is a complex response to a variety of stimuli such as trauma, 
infection, and injury (3, 4). Celsus (30sc to 38Ao) described the cardinal signs of 
inflammation: heat, redness, swelling, and pain (5) . The physiological role of the 
acute inflammatory response is protective. Tissue homeostasis after insult is 
restored by targeted destruction of invading organisms or removal of noxious 
substances; a process of complete repair follows, returning the damaged tissues 
to their original morphology and function. Failure of resolution of acute 
inflammation leads to persistence of the insult and chronic inflammation. In 
chronic inflammation, the further host response is characterized by accumulation 
of inflammatory cells and mediators and activation of the acquired immune 
system. In chronic inflammatory lesions, much of the tissue damage observed is 
mediated by host cellular responses rather than the initiating infection or trauma. 
The mechanisms associated with tissue injury such as phagocytosis, leukocyte 
migration and vascular permeability were described in the 19th century, while the 
chemical mediators responsible for these events were revealed in the second 
half of the 20th century. 
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Eicosanoids, prostaglandins, leukotrienes, lipoxins, platelet-activating 
factor (PAF), resolvins, and other lipid mediators are produced in a temporal 
fashion to initiate, control , and terminate the process of acute inflammation (6-
1 0). Along with protein and peptide endogenous mediators of inflammation 
(described below), eicosanoids functioning to regulate and resolve inflammation 
in healing bone are the focus of this dissertation. Faulty modulation of soluble 
factors and cells involved in wound healing results in tissue damage and a failure 
to return to homeostasis without scarring. However, appropriate specific signals 
trigger mobilization of inflammatory cells and elimination of pathogens and 
damaged tissue, which results in functional restoration of the organ (11 ). 
1.1.1 Early events in inflammation 
The inflammatory events that comprise acute inflammation are best 
exemplified in wound healing. The process of wound healing involves highly 
coordinated phases of blood clotting, inflammation, granulation tissue formation, 
re-epithelialization, and remodeling. This mechanism depends on specific 
interactions among multiple cell types and is stimulated and mediated by growth 
factors and matrix components. Each population of cells acts in response to 
factors that are temporally released as normal healing occurs. 
The process of acute inflammation that initiates wound healing is also the 
first step in bone healing. In both cases, disruption in tissue structure and 
4 
function triggers removal of the tissue components that were damaged through 
an inflammatory process. This process of inflammation is then inhibited and the 
repair of the tissue components is initiated. The major difference between wound 
healing and bone healing is the type of extracellular matrix that needs to be 
repaired. Bone healing is explained in details in section 1.2.7 below. 
Tissue disruption causes bleeding and initiates the coagulation cascade, 
forming a blood clot. Normal hemostatic processes arrest bleeding from 
damaged vessels and provide a temporary barrier at the wound site. Platelet 
activation, in the form of degranulation and adhesion, leads to hemostasis and 
chemotaxis of inflammatory cells. The clot is formed from platelets and other 
blood cells together with proteins such as fibrin , fibronectin, vitronectin, and 
thrombospondin (12). 
In the early stages of inflammation, constitutively expressed intracellular 
proteins are released from damaged cells, and pathogens in the inflamed tissue 
trigger cytokine production (13-16). In response, neurons release bioactive 
peptides, which may increase edema (16). Local mast cells and resident 
macrophages in the damaged tissue are first to respond, releasing histamine, 
eicosanoids, cytokines, proteases, and chemokines (17, 18). These mediators 
cause vasodilatation and activation of mast cells and neurons, thereby facilitating 
leukocyte recruitment from the blood (19). TNF-a and leukotrienes produced by 
mast cells prime polymorphonuclear cells (PMN), resulting in release of elastase, 
5 
which allows PMN surface integrins to interact with extracellular matrix (ECM) 
proteins (20). 
The inflammatory phase of healing (injury to 5 days) is defined by PMN 
infiltration with subsequent replacement by macrophages and lymphocytes. This 
phase is initiated by recruitment of PMN to the wound site within minutes. PMN 
function primarily to clean the wound environment by production of reactive 
oxygen species (ROS), especially superoxide anion (02-) that kill bacteria, and by 
phagocytosis of necrotic material. The initiating signals are platelet-derived 
growth factors or degradation products of fibrin and other matrix components, but 
also formyl methionyl peptides cleaved from bacterial proteins (21 ). 
Leukocytes respond to chemotactic signals from endothelial cells, such as 
IL-8, migrate through the walls of blood vessels in the vicinity of the wound site, 
and enter the extravascular space. This migration is actively mediated by 
endothelial cells through wound-upregulated expression of selectin molecules, 
which slow down the leukocytes and pull them from the blood stream. Stronger 
adhesions form subsequently through integrins, and leukocytes migrate between 
the endothelial cells in the process of diapedesis. PMN are predominant in the 
first 6 hours, and their numbers decrease within the first 24 hours, disappearing 
within 72 hours. Among other factors, PMN are responsible for the release of 
cytokines such as TNF-a and interleukin-1 (IL)-1, which lead to release of 
catecholamines and corticosteroids. TNF-a is also involved in the signaling of 
PMN apoptosis (22) . Together with stimulation by TNF-a, chemokines and the 
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complement protein C5a, these events trigger release of proteinases, 
hydrolases, antibiotic proteins, and oxidants (23). Oxidants activate matrix 
metalloproteinases (MMPs) and inactivate protease inhibitors (24) . 
Monocytes are recruited within 24-48 hours after the wound and 
differentiate into activated macrophages that function in clearing of the residual 
pathogenic organisms. Macrophages produce growth factors, cytokines, 
chemokines, and prostaglandin E2 (PGE2). MMP- and elastase-induced 
cleavage of TNF as well as release of transforming growth factor (TGF)-~ from 
macrophages and monocytes results in chemotaxis and activation of additional 
PMN. Although optimal healing requires presence of all the different populations 
of leukocytes, only macrophages are an absolute necessity. Macrophages 
produce growth factors and other cytokines, which then promote fibroblast 
migration, proliferation, and collagen synthesis. Fibroblasts proliferate as an 
early response to the injury and within 3-4 days migrate into the blood clot. A 
more detailed review of macrophage function is given in section 1.1.2 below. 
Maturation and remodeling of the scar begins during the fibroblastic phase 
and is characterized by the reorganization of previously synthesized collagen. In 
the skin, the fibroblastic phase is the second phase of wound healing (days 4 
through 12). Tissue continuity is restored during this phase, as are blood vessels 
and epithelium. Granulation tissue is formed by inflammatory cells, apposition of 
matrix, and growth of new capillaries (25). Cytokines and inflammatory cells 
attract fibroblasts and myofibroblasts into the wound . These signals are 
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mediated by the ECM and as a result, the cells proliferate. In addition, the 
fibroblasts deposit collagen and glycosaminoglycans, resulting in a significant 
increase in tensile strength. 
TNF-a regulates angiogenesis, collagen content, re-epithelialization, and 
expression of various growth factors and their corresponding receptors (26). In 
the bone tissue, TN F-a stimulates osteoclast differentiation and function, inhibits 
osteoblast differentiation, and induces the production of inflammatory factors (27-
29). TGF-13 is produced by several cells at the wound site (30, 31 ). There are 3 
TGF-13 isoforms, and the balance between the different isoforms may be critical 
for healing (32) . Connective tissue growth factor (CTGF) is a downstream 
mediator of the action of TGF-13 on connective tissue cells, stimulating 
proliferation and production of matrix (33). 
Collagen is degraded by MMPs. The net amount of collagen in the wound 
is the result of a balance between collagen synthesis and collagenolysis. 
Macrophages trigger the recruitment of lymphocytes (34), which infiltrate the 
wound area and regulate macrophages as well as other cells by expression of 
cytokines. The resulting inflammatory response is required for the apposition of 
ECM. After 2-3 weeks, there is an increase in collagenase production and the 
collagen is remodeled along planes of stress, increasing the strength of the 
wound . TGF-13 together with PDGF may be involved in granulation tissue 
contraction (35, 36). This remodeling phase lasts approximately one year, during 
which the wound becomes less cellular and less vascularized. 
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Cells are removed from the wound area by necrosis, migration, or 
apoptosis. Necrosis is usually a minor phenomenon in normal repair, and 
healing proce,eds without excessive inflammation. Apoptosis is a common way 
by which cells are removed without triggering an inflammatory response. 
Acute inflammation and its resolution are the optimal sequence of events 
in wound healing leading to catabasis (return to health). The type of 
inflammatory stimulus and its duration determine the production of chemotactic 
factors and subsequently the types of cells acting in each stage of inflammation. 
This pattern of events activated in acute inflammation is similar in bone healing, 
where regeneration of the tissue depends on adequate signals from the immune 
cells. Bone healing and return to function depend on proper resolution of 
inflammation. 
1.1.2 Macrophages in acute inflammation 
Macrophages are important factors in acute inflammation and bone 
healing . Macrophages are present in all tissues and play an important role in 
initiating , maintaining and resolving inflammation. Macrophages respond to 
stimuli from innate- or antigen-specific immune cells , in addition to signals 
produced by other macrophages. 
Macrophages differentiate from peripheral-blood mononuclear cells 
(PBMCs), which develop from myeloid progenitors, termed 
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granulocyte/macrophage colony-forming units (GM-CFUs). GM-CFUs 
differentiate into monoblasts, pro-monocytes, and then monocytes, which are 
released from the bone marrow into the circulation (37). As part of their normal 
function in inflammation, macrophages produce pro-inflammatory cytokines, such 
as TNF-a, IL-6, and IL-12. These functions are shared by different macrophage 
populations, and there is evidence of plasticity and reversibility (38) . In the bone 
tissue, IL-6 was found to increase osteoclast differentiation (39). 
Macrophages are not a homogeneous population. Functional 
subpopulations were defined in human (40) and mouse macrophages (41, 42). 
Human macrophage subpopulations have pro- and anti-inflammatory functions 
similar to those described in the mouse system. The phenotypes of 
macrophages with specific functions are described as "classically activated" (Ca-
M<t>), wound-healing, and regulatory macrophages. In mice, M1 macrophages 
(Ca-M<t> in humans) and M2 macrophages (wound healing in humans) each 
constitute approximately 50% of the total macrophage population (43). 
Ca-M CD, which constitute 90% of the monocyte population in humans, 
function in response to interferon (IFN) -y, lipopolysaccharide (LPS), and TN F-a, 
and produce large amounts of inflammatory cytokines and reactive oxygen 
intermediates. Ca-MCD exhibit cytotoxic activity, which mediates resistance 
against tumors and clearance of infection. Toll-like receptors (TLR)s (13) and 
nucleotide oligomerization domain (NOD)-Iike receptors (NLR)s on macrophages 
mediate the inflammatory response to infection, functioning as pattern 
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recognition receptors (PAMPs) by sensing microbial antigens (44) . Pro-
inflammatory cytokines produced by Ca-M<l> are important for host-defense but 
can cause extensive damage to the host. 
In contrast to the classical phenotype, wound healing macrophages are 
induced in response to IL-4 produced by basophils, mast cells, and T helper 
(T H)2-type immune responses in the lung and the intestines (45). Wound healing 
macrophages are also associated with parasitic infections (46, 47) and may 
contribute to the production of ECM (48). These macrophages regulate matrix 
production and promote cell proliferation through the synthesis of TGF-J3, TN F-a, 
bFGF, PDGF and VEGF (49). If dysregulated, the function of wound healing 
macrophages can also be detrimental to the host, causing tissue fibrosis . An 
example of tissue damage due to macrophage dysregulation would be the 
innocent bystander effect upon surrounding normal tissue cells in cases of 
schistosomiasis (46). 
A third type are regulatory macrophages, which are generated in response 
to glucocorticoid release (50). These macrophages also arise during the later 
stages of adaptive immune responses, where their role is to limit inflammation 
(51) . In addition, regulatory macrophages differentiate in response to 
prostaglandins (52), apoptotic cells (53) , IL-1 0 (54), and certain ligands of 
GPCRs (55). Most of the regulatory macrophages require two stimuli in order to 
induce their anti-inflammatory activity. These macrophages can present antigens 
to T cells but do not contribute to the production of ECM (56). 
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Macrophage function is modulated by signals from the surrounding cells, 
some of which induce macrophage apoptosis. Macrophages express 
prostaglandin receptors, EP 4 more abundantly than others. EP 4 mainly couples 
to the G5 subunit of adenylate cyclase and increases intracellular cAMP levels 
upon PGE2 ligation. In animals, EP4 signaling protects against experimental 
inflammatory bowel disease (56) and reduces inflammatory bone resorption (49). 
PGE2 suppresses production of a number of chemokines in LPS-stimulated 
human primary macrophages. PGE2 pre-treatment selectively diminishes 
responses to various proinflammatory stimuli by macrophages but not by 
vascular endothelial cells or smooth muscle cells, emphasizing the role of 
macrophages in resolution of inflammation (57). 
Macrophages have a wide spectrum of activity and are able to respond to 
a variety of stimuli. In bone, macrophages function as resident cells in initiation 
of inflammation in response to injury and infection. In addition, the function of 
macrophages is also relevant to bone healing, where they modulate the function 
of osteoblasts (58) and osteoclasts (59-61 ). Osteal macrophages were shown to 
be associated with areas of bone remodeling, and to contribute to osteoblast 
maturation and mineralization, detailed in section 1.2.5 below. 
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1.1.3 Factors that regulate acute inflammation 
The cytokines involved in the initial phase of inflammation are IL-4, IL-8, 
IL-10, IL-12, IL-13, IFN-y, chemokine (C~C motif) ligand (CCL) -5, granulocyte 
macrophage colony-stimulating factor (GM-CSF), and monocyte chemotactic 
protein (MCP)-1. In contrast to these factors, TGF-~ levels increase to peak at 
24h, suggesting a critical role in the resolution phase, described in section 1.1.4 
below. 
The production of pro- and anti-inflammatory -eicosanoids is orchestrated 
by leukocytes. Membrane phospholipids are metabolized by phospholipase A2 
(PLA2) to w-6 and w-3 polyunsaturated fatty acids (PUFA), while platelet 
activating factor (PAF) acetylhydrolase converts them into PAF. Arachidonic acid 
is converted by cyclooxygenase (COX) 1 and COX-2 to prostaglandin G2. COX-
1 is constitutively expressed, while COX-2 produces high levels of prostanoids 
during inflammation (62). Prostaglandin G2 is further metabolized to 
prostaglandin H2, which in turn can be converted to prostaglandin E2 by PGE 
synthase (PGES). Cytosolic PGES is constitutively expressed (62, 63), while 
membrane-associated PGES -1 is induced by pro-inflammatory stimuli (64, 65). 
The production of PGE2 triggered by pathogens and cytokines causes an 
increase in the permeability of blood vessels. 
Arachidonic acid can be also metabolized by the lipoxygenase pathway to 
leukotrienes, which are inflammatory mediators that signal through GPCRs (65, 
66). Lipoxygenases (LOs) are non-heme, iron-containing enzymes that catalyze 
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the oxidation of PUFA. LOs have been shown to modulate the activity of 
mitogen-activated protein kinase (MAPK) (67-69) , as well as proliferation or cell 
survival (67, 70-72). There are three major human LOs: arachidonate:oxygen 5-
oxidoreductase (5-LO), arachidonate:oxygen 12-oxidoreductase (12-LO) , and 
arachidonate:oxygen 15-oxidoreductase (15-LO). 5-LO is mainly produced in 
myeloid cells, 12-LO in platelets, and 15-LO in monocytes and tissue resident 
cells. The expression of 15-LO is increased in several pathological conditions. 
In addition to synthesis of pro-inflammatory mediators, LOs also catalyze the 
production of anti-inflammatory and pro-resolving factors. 
PUFA have important roles in bone repair (73-75). Prostaglandins of the 
E series have complex actions as they can stimulate both bone resorption and 
bone formation in vitro and in vivo. In primary rat calvarial osteoblast cultures 
(76, 77) and MC3T3 cells (78), PGE2 stimulates mineralization and activity of 
ALP. PGE2 was found to be increased in fracture regions (79, 80) and fracture 
healing was found to be delayed in COX2-deficient mice relative to COX1 
deficient mice or wildtypes (75) . Mechanical stress, which is necessary for 
fracture healing , is mediated by PGE2 and COX2 (81-83). The functions of 
cytokines and PUFA in bone tissue are described in further detail in section 1.2.6 
below. 
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1.1.4 Resolution of inflammation 
The possible outcomes of acute inflammation are resolution and 
catabasis (return from disease), healing by scarring, 'or abscess formation (84). 
Chronic inflammation plays a major role in the latter two outcomes of acute 
inflammation, becoming independent of its initiating factor, especially in cases of 
massive trauma, necrosis, and hemorrhage followed by resuscitation. 
During the resolution phase of acute inflammation, monocyte populations 
increase to approximately 80% of the exudate cell population (40, 85) . The 
process of resolution employs multiple mechanisms: apoptosis (86), receptor 
unresponsiveness, receptor down regulation by high concentrations of ligands, 
upregulation of anti-inflammatory molecules such as the IL-1 receptor antagonist 
or soluble TNF-receptor, inhibition of chemokine expression by anti-inflammatory 
factors such as IL-10 (87) and TGF-13 (88-90), or cleavage by proteases (91) . 
MMPs regulate inflammation by cleavage of chemokines into anti-inflammatory 
products (92). PGE2 feeds back to inhibit COX2 and 5-LO in PMN, while 
inducing 15-LO (84). 
Additional stop signals such as adenosine (93), CD200 (94) and gp4981 
(95) are part of a wide array of signals involving protein-protein interactions that 
reduce inflammation in the early stage. The autonomic nervous system also 
issues stop signals as cholinergic discharge blocks the release of TNF from 
macrophages (96). 
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The active process of resolution is characterized by a shift in the 
production of pro-inflammatory mediators to anti-inflammatory mediators (97-99) . 
The actions of two different lipoxygenases (5, 12 or 15-LO) ·on the same 
arachidonic acid molecule (a process termed transcellular biosynthesis) results in 
the production of lipoxins. Lipoxins are anti-inflammatory mediators derived from 
arachidonic acid that function through specific receptors on leukocytes that 
regulate their function. Studies show that 15-LO expression and lipoxin 
production in acute inflammation are associated with resolution (98) . 
Aspirin, a widely used non-steroidal anti-inflammatory drug (NSAID), has 
inhibitory action on the production of pro-inflammatory metabolites. Recently it 
has been found that aspirin also mediates a shift in processing of PUFA to 
production of anti-inflammatory mediators (100). The mechanism of aspirin 
action is detailed in section 1.1.4.1 below. The production of LXs and aspirin-
triggered LXs by 5-LO has been shown to block PMN infiltration (1 01, 1 02). 
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are 
the major w-3 PUFA derived from fish oil. When ingested by humans, these 
compounds are involved in many physiological processes, including regulation of 
cardiovascular, immune, hormonal, metabolic, neuronal, and visual functions 
(1 03, 1 04). At the cellular level, these actions are mediated by changes in 
membrane phospholipid structure, interference with eicosanoid intracellular 
signaling, and regulation of gene expression (1 05). Deficiency in DHA has been 
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associated with neuronal malfunction, cancer, and inflammation (1 01, 1 02). 
Eicosanoids and polyunsaturated fatty acids first appear 4h after the initiation of 
inflammation (106). The importance of these mediators for bone metabolism has 
been demonstrated in both animal (107) and human studies (108, 109), showing 
that supplementation of the diet with EPA, DHA, and gamma-linolenic acid (GLA) 
is associated with reduced resorption of bone. The actions of EPA and DHA in 
the skeletal system are reviewed in detail in section 1.2.6 below. 
Resolution of inflammation in mice has been defined by operative and 
quantitative parameters: the maximal number of PMN present during the 
inflammatory response (Psi(max)), the time when Psi(max) occurs (T(max)), and 
the resolution interval from T(max) to the time when neutrophil numbers reach 
half Psi(max) (R(i)) (1 06) (Fig. 1 ). 
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Figure 1 - Resolution indices 
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Figure 1 - Resolution indices defined in zymosan-induced peritoneal 
inflammation in mice. Time course analysis of cell composition of peritoneal 
lavage. 4JMax- neutrophil count at maximal infiltration, T Max- time of the maximal 
PMN infiltration. T 5o- the time when neutrophil infiltration is decreased to 50% 
(R5o)' Ri - resolution interval - the period between T max and T 50. IPMN =Mono - time 
point at which PMN numbers are the same as those of the monocytes. Adapted 
from Bannenberg et al. (1 06) 
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1.1.4.1 Resolvins mediate resolution of inflammation 
Resolvins of the E series are enzymatically-generated metabolites 
derived from EPA. They were detected in resolving inflammatory exudates and 
were shown to possess potent anti-inflammatory and immunomodulatory actions 
in the nanogram dose range in vivo, and their potency was found to be 
comparable to higher doses of dexamethasone or aspirin (11 0). Synthesis of 
resolvins occurs by a specific interaction between leukocytes and endothelial 
cells. Resolvins promote uptake and clearance of apoptotic PMN, reducing 
traffic and production of pro-inflammatory cytokines (111 ). Signaling pathways 
leading to PGE2 and PGD2 cause the transcription of enzymes required for the 
production of resolvins (99, 110, 112). Aspirin was also found to stimulate 
production of these mediators (99, 11 0). Aspirin acetylates COX-2 in vascular 
endothelial cells to generate 18R-hydroperoxy-eicosapentaenoic acid (18R-
HEPE) from EPA. The production of 18-HEPE in vivo is related to dietary intake 
of EPA (100) . In healthy human volunteers given EPA and aspirin , RvE1 plasma 
values ranged from 0.1-0.4 ng/ml (100) . 18-HEPE is later processed by 
leukocytes to resolvin E1 (11 0) or E2 (RvE2; 5S, 18R- dihydroxy-
6E,8Z, 11Z, 14Z, 16E- EPE) (113) . The conversion of 18R-HEPE is catalyzed by 
5-LO, which sequentially inserts molecular oxygen to produce 5S-hydroperoxy-
8R-hydroxy-EPE and 5S(6)-epoxy-18hydroxy-EPE (Fig. 2). 
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Figure 2- RvE1 biosynthesis. RvE1 is synthesized from EPA by cell-cell 
interactions through aspirin- or P450-dependent pathways. In the aspirin-
dependent synthesis, aspirin acetylates endothelial COX-2 which metabolizes 
EPA. Otherwise, EPA can be processed by P450 originating from bacteria or 
tissues. The product is 18-HEPE, which is further processed by neutrophilic 
lipoxygenases (5-LO) to generate RvE 1. Adapted from ref. (1 00, 11 0) 
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Aspirin also increases production of 188-hydroxyeicosapentaenoate (188-
HEPE). The 188-HEPE-derived 188-RvE1 was found to bind to the receptors 
ChemR23 and BLT-1 with increased affinity relative to 18R-RvE1, although 
dehydrogenation inactivates this derivative more rapidly. Functionally, 188-RvE 1 
was found to be similar to 18R-RvE1, by reducing PMN infiltration, by decreasing 
levels of proinflammatory cytokines, and by enhancing macrophage phagocytosis 
of zymosan, Escherichia coli, and apoptotic PMN (114). Interestingly, Candida 
albicans was found to produce RvE1 identical to that produced by human cells 
(115). 
RvE1 was found to reduce the magnitude of the inflammatory response in 
the lung, skin, eye, periodontium, and gastro-intestinal tract. 
Lung: In a murine model of asthma, RvE1 caused a decrease in airway 
eosinophil and lymphocyte recruitment and mucus scores (116). RvE1 inhibited 
the production of IL-23 and IL-6, and increased IFN-y in the lung (117). In self-
limited airway inflammation, RvE1 was found to regulate the migration of NK cells 
in vivo and their cytotoxicity in vitro (118). In Fat-1 transgenic mice, which are 
able to convert w-6 to w-3 PUFA, challenging with allergen was found to induce 
expression of pro-inflammatory cytokines at lower levels, increased expression of 
RvE 1 and decreased airway inflammation ( 119). 
In a model of acid injury followed by bacterial infection in the murine lung, 
pre-treatment with RvE1 decreased PMN accumulation by 55% and increased 
bacterial clearance, increasing survival (120). In this model, pro-inflammatory 
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mediators including IL-1 p, IL-6, HMGB-1, MIP-1 a, keratinocyte-derived 
chemokine, and MCP-1 were significantly decreased by RvE1, independent of 
the anti-inflammatory mediators IL-10 and~- In an ovalbumin-sensitized 
model :of asthma, administration of RvE1 resulted in decreased eosinophil and 
lymphocyte recruitment. In addition, RvE1 caused a reduction in T H2 cytokine 
and airway hyper-responsiveness, decreasing airway inflammation (121). 
Cardiovascular system: In rats that underwent ischemia/reperfusion, 
preventive treatment with RvE1 reduced infarct size. RvE1 increased viability 
and decreased apoptosis in H9c2 cardiomyocytes exposed to hypoxia or 
hypoxia/reoxygenation (122). In these cells, RvE1 increased phosphatidyl-
inositol 3 kinase (PI3K), Akt, p42/44 MAPK, while inhibiting caspase-3 and 
phosphorylation of p38 MAPK. Both in vivo and in vitro, the epithelial growth 
factor (EGF) receptor tyrosine kinase inhibitor AG1478 prevented the actions of 
RvE1. 
Eye: In a model of migration of human epithelial corneal cells, the same 
inhibitor (AG1478) blocked RvE1-dependent increases in the phosphorylation of 
the EGF receptor (EGFR), Akt, p38 MAPK, GSK-3a/p, and paxillin . The 
increases in cell migration induced by RvE1 were blocked by specific inhibitors of 
PI3K and p38. The stimulation of EGFR/PI3K/Akt phosphorylation and cell 
migration was attenuated by the matrix metalloproteinase inhibitor GM6001 or 
the specific heparin-bound EGF-Iike growth factor inhibitor CRM197 (123). In 
mice exposed to desiccating conditions, RvE1 increased tear production after 2 
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and 4 days. This action was correlated with a decrease in a-smooth muscle actin 
and COX-2 expression, which are upregulated in desiccating conditions. In 
addition, there was a decrease in CD4+ T cells and CD11 b+ cells after RvE1 
treatment (124). In a different study, RvE1 reduced the corneal permeability due 
to desiccating conditions and maintained goblet cell density (125). 
In stromal keratitis (SK), a chronic eye lesion caused by HSV-1 infection, 
RvE1 significantly reduced lesions and angiogenesis in mice. RvE1 inhibited 
infiltration of PMN as well as T H1 and T H17 cells. These actions were correlated 
with increased levels of IL-10 and reduced production of IL-6, IFN-y, IL-17, KC, 
VEGF-A, MMP-2, and MMP-9, which are factors known to mediate corneal 
neovascularization and SK pathogenesis (126). Goblet cells in the conjunctiva 
secrete mucins for eye protection. In rat goblet cells, RvE1 blocks L TD4-
stimulated excessive secretion of mucins by preventing increases in intracellular 
calcium and phosphorylation of p42/44 MAPK (127). 
Leukocytes: RvE1 reduces pro-inflammatory dendritic cell migration to 
inflamed tissues and IL-12 production (100, 128) (Table 1). RvE1 acts on pro-
resolving dendritic cells to remain at the inflammatory site and induce apoptosis 
of activated T cells (129). RvE1 regulates the expression of adhesion molecules 
by leukocytes, reducing leukocyte rolling in venules of mice (130). Leukotriene 
84 (L TB4) is a known pro-inflammatory mediator. L TB4 was shown to induce the 
production of LL-37, an antimicrobial peptide. RvE1 inhibits this action in PMN 
(131 ). In mice, RvE1 suppressed suture- and IL-113-induced angiogenesis, 
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reduced infiltration of PMN and macrophages, and reduced mRNA expression of 
pro-inflammatory cytokines (132). 
Gastro-intestinal system: In a murine model of self-resolving 
inflammation, resolution was accelerated by treatment with aspirin-triggered L~ 
analog, RvE1, or 10, 17S-docosatriene (1 06, 133). The inhibitory actions of RvE1 
and 10, 17S-docosatriene were maximal at 12h, causing a 30-80% inhibition of 
pro-inflammatory cytokines and chemokines. In vitro, human pancreatic islets 
stimulated with LPS expressed increased levels of the pro-inflammatory 
cytokines IL-8, MCP-1 and tissue factor (TF) (134). A 24h treatment with RvE1 
was found to reduce the induction of these cytokines and their apoptotic action. 
In intestinal epithelial cells, RvE1 detoxified LPS, inducing the expression and 
activity of alkaline phosphatase (ALP). RvE1 also improved disease indices in 
dextran sulfate sodium-induced colitis, an action found to be mediated by ALP 
(135). 
RvE1 mimics the insulin-sensitizing and anti-steatotic actions of w-3 
PUFAs in ob/ob mice, a model of insulin resistance and fatty liver disease (136). 
Treatment with RvE1 was also shown to prolong renal allograft survival in 
transgenic mice expressing human LXA4 receptors (137). 
Taken together, the data from a variety of inflammatory disease models in 
different organ systems paint a picture of a universal inflammation resolving 
system that acts through pathways that appear specific to each organ system. 
The pathways of action of resolution agonists in bone are not well defined. 
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What is known to date is that RvE1 directly inhibits osteoclast 
differentiation in vitro. RvE1 decreased RANKL-induced osteoclast growth and 
the resorption of dentin discs. RvE1 increased the population of small osteoclast 
precursors and decreased that of larger precursors (2). 
Regulation of pro-resolving macrophage function: In addition to 
inhibition of PMN infiltration, RvE1 was also found to regulate pro-resolving 
macrophage functions (Fig. 3) . 
Apoptosis of leukocytes is an important step in resolution (138, 139). 
Apoptotic cells trigger production of TGF-[3 and IL-1 0, cytokines that can promote 
resolution and wound repair (140, 141). RvE1 was found to enhance CD55-
dependent clearance of apoptotic PMN from epithelial surfaces (142). RvE1 was 
shown to upregulate the expression of CCR5, a chemokine receptor that inhibits 
chemokine signaling during resolution of inflammation (143). Silencing of 
macrophages is required in the late stages of resolution. While RvE1 enhances 
phagocytosis of apoptotic PMN early in resolution, RvE1 was found to decrease 
the ability of macrophages to engulf apoptotic PMN in the terminal phase of 
resolution. This change in function coincides with the appearance of CD11 b10w 
macrophages (144). 
In human platelet-rich plasma, RvE1 blocked thromboxane- and 
adenosine diphosphate (ADP) - but not collagen-stimulated platelet aggregation 
(130) . Blocking of ADP resulted in decreased P-selectin mobilization and actin 
polymerization (145) . Evidence shows that chronic vascular inflammation 
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contributes to atherosclerosis (146). RvE1 is one of the mediators that protect 
against atherosclerosis by contro.lling the magnitude of the local inflammatory 
response (147). In a different study, RvE1 was found to decrease 
phosphorylation of the PDGF receptor-13 and to block PDGF-stimulated migration 
of human saphenous vein smooth muscle cells (148). In a periodontal disease 
relevant study, macrophages were found to have decreased phagocytic activity 
in Localized Aggressive Periodontitis (LAP). RvE1 at concentrations of 0.1-
1 OOnM was able to rescue the function of macrophages, suggesting an impaired 
mechanism of resolution in LAP patients (149). 
Metabolism of RvE1: Mammalian cells have at least four distinct 
pathways to metabolize RvE1, and the inactive products are: 10, 11-dihydro-
RvE1, 18-oxo-RvE1, 20-carboxy-RvE1 , and 19-hydroxy-RvE1. The metabolic 
products derived from RvE1 were found to be specific to cells, tissues, and 
species in which they are produced (150). RvE1 inactivation was found to occur 
in murine lung by catalysis of conversion to 18-oxo-RvE1, compound which lacks 
the ability to control PMN recruitment in zymosan-induced peritonitis ( 151). 
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Figure 3 - Resolution mediators act on leukocytes 
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Figure 3 - Resolution mediators act on leukocytes. Upon initiation of 
inflammation, mast cells and resident macrophages recruit PMN by producing 
chemotaxis factors, and these PMN migrate by diapedesis from blood vessels 
i 
into the inflamed tissue. Production of specialized pro-resolving mediators 
inhibits PMN migration and function. Pro-resolving mediators stimulate 
monocyte recruitment, phagocytosis of apoptotic PMN and their clearance 
through the lymph system. Adapted from ref. (152). 
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Table 1 - Summary of RvE1 actions in multiple cell types 
Cell type Action 
Neutrophils Inhibits transmigration (110) and leukocyte rolling (130). 
Blocks fMLP-stimulated superoxide generation in healthy and LAP (155) 
Blocks L TB4-induced LL-37 production (131) 
Monocytes/ Stimulates non-phlogistic phagocytosis of apoptotic PMN (111) 
Macrophages Increases MAPK activation in monocytes (100) 
Reduces the number of macrophages that ingest apoptotic PMN (144) 
Increases clearance of macrophages from inflammation areas (111) 
Dendritic cells Increases apoptosis of activated T cells (129) 
T-cells Up-regulates CCR5 expression (143) 
Platelets Blocks platelet aggregation (130, 145, 149) 
Corneal epithelial Increases cell migration (123) 
Mucosal Increases CD55 expression, increases apical clearance of PMN (142) 
epithelial cells Increases alkaline phosphatase expression and activity of bacterial 
detoxification ( 135). 
Adipocytes Increases adiponectin in adipose tissue collected from ob/ob mice ex 
vivo (136) 
· Myocytes Preventive treatment with RvE1 reduced infarct size (122) 
Pancreatic islets Reduces pro-inflammatory markers (134) 
Osteoclasts Decreases osteoclast differentiation (2) 
Osteoblasts Blocks IL-6 inhibition of OPG expression (See text). 
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1.1.4.2 ChemR23 are G-protein-coupled receptors that mediate the action 
of RvE1 
ChemR23 is a GPCR that has a role in both pro- and anti-inflammatory 
processes, depending on the ligand. GPCRs span the membrane seven times 
and mediate a wide variety of biological and pharmacological functions. Most 
GPCRs rapidly lose their responsiveness after ligand stimulation. GPCRs are 
endocytosed as part of their function and are targeted for degradation or for 
recycling (157). Receptor internalization does not necessarily cause signal 
termination (158, 159). 
Expression: ChemR23 is expressed in multiple cell types throughout the body, 
including myeloid cells, plasmacytoid dendritic cells, CD4+ T lymphocytes (160) , 
chondrocytes (161) , bone tissue during development (162), adipocytes (163-
166), vascular smooth muscle cells (148) , endothelial cells (167), intestinal 
epithelial cells (135), and liver cells (168) . ChemR23 functions in both the innate 
and adaptive immune responses (169). ChemR23 is highly upregulated by 
treatment with inflammatory cytokines such as TNF-a and IFN-y. Although 
Chem23 was found to be up-regulated in peripheral human blood monocytes 
exposed to TN F-a (1 00) , in epithelial cells, TN F-a appears to down-regulate 
ChemR23 (142). The human ChemR23 receptor is conserved in evolution , with 
80.3% protein identity and 82.6% DNA identity with the mouse ChemR23 
receptor. 
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Signaling: GPCRs use multiple pathways for transduction of receptor 
signals. p42/44 MAPK, ERK 5, and p38 MAPK have been shown to mediate 
GPCR signaling. MAPKs are a family of enzymes that participate in many 
cellular pathways such as differentiation, proliferation, motility, and death. In 
human articular chondrocytes , stimulation with chemerin (a peptide ligand for 
ChemR23) resulted in phosphorylation of p42/44 MAPKs and Akt (Ser 473) 
(161). 
Both p42/44 MAPKs and Akt function in the main pathways that transduce 
inflammatory signals (170, 171). ChemR23 functions as a receptor for RvE1, 
chemerin and possibly other ligands. The binding of RvE1 to this receptor in 
HEK-ChemR23 cells is diminished by the presence of chemerin (172) . In 
peripheral blood monocytes and HEK-ChemR23 cells, RvE1 increases 
phosphorylation of p42/44 MAPK. In addition , in CHO-hChemR23-transfected 
cells, RvE1 caused phosphorylation of Akt and p42/44 MAPK (173) . ChemR23 
was found to attenuate the nuclear factor kappa 8 (NF-kB) in response to RvE1 
through activation of phosphorylation pathways (156) . Treatment with pertussis 
toxin blocked activation of p42/44 MAPK and NF-kB inhibition by RvE1 (100) . 
BL T-1 is another GPCR found to mediate the actions of RvE1 in PMN by 
inhibiting the activity of adenylate cyclase. In BL T-1 knockout mice, low doses of 
RvE1 had reduced anti-inflammatory actions in a model of peritonitis. Higher 
doses reduced PMN infiltration, indicating binding as a partial agonist (172). 
Interestingly, RvE1 binding to BLT-1 appears to be partially shared with LT84 and 
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part of the actions of RvE1 due to competitive inhibition, ChemR23 functions as a 
pro-resolving receptor upon RvE1 binding. ChemR23 has also a protein ligand, 
chemerin. The dissociation constant (kD) of RvE1 is in the picomolar range and 
the kD of chemerin is in the micromolar range, bringing into question the 
physiologic significance of the protein ligand (152). 
1.2 Bone cellular components 
Bone tissue function is determined by the physical and metabolic 
requirements of the organism. Systemic hormones as well as local factors 
operate directly on bone remodeling cells or through the interaction of these cells 
with the immune system. Bone develops through two different mechanisms: 
intramembranous or endochondral ossification. In intramembranous ossification, 
osteoblasts differentiate from the mesenchymal precursor cells that aggregate at 
the site of bone formation. This process results in the formation of the skull and 
parts of the clavicles. The rest of the skeleton forms by an endochondral 
ossification, by which cartilage forms the frame of future bones. Chondrocytes in 
the region of the future bones proliferate, produce matrix, hypertrophy, and 
become the target of vascular invasion. Osteoblasts later deposit mineralized 
matrix on the cartilage template. 
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1.2.1 Osteoblasts differentiate from mesenchymal precursors and produce 
mineralized extracellular matrix 
1.2.1.1 Transcriptional regulation of osteoblast differentiation 
Pluripotent stromal cells differentiate into adipocytes and osteoblasts. The 
differentiation process is regulated by both protein factors and lipid mediators. 
Osteoblastic differentiation is characterized by expression of ALP as a 
preosteoblastic marker. 
Runx2 is an essential factor for bone development. It appears early in 
skeletal development (174), and its expression is constitutive once skeletal 
development has started. Together with several other transcription factors, 
Runx2 regulates the differentiation into osteoblast and chondrocyte lineages. 
Skeletal development in Runx2 knockout animals does not proceed beyond the 
cartilage anlage stage (175, 176). Mesenchymal cells in the bone marrow 
proliferate and express Runx2 and distal-less homeobox-5 (Dix5) (154, 17 4, 177-
179). 
Msh homeobox homologue (Msx)-2 and bagpipe homeobox homolog 
(Bapx)-1 were shown to increase Runx2 expression (180, 181), while homeobox 
A (Hoxa)-2 inhibit the expression (175, 182). Other factors that modulate the 
expression of Runx2 are bone morphogenetic proteins (BMPs) (174). Indian 
hedgehog (lhh) is a growth factor that controls Runx2 expression during 
development of long bones (183). Runx2 action can also be regulated by CBF-P 
35 
(184), SMAD proteins (185), SOX9 (186), TWIST (183), histone deacetylases or 
histone deacetylases accessory factors (187). Runx2 activity is also controlled 
by transcriptional modification. lntegrins activate the MAPK pathway, resulting in 
phosphorylation and stimulation of Runx2 transcriptional activity (185). 
The regulatory sequences of most of the genes required for production of 
ECM contain binding sites for Runx2 (174). Runx2 regulates the expression of 
osteocalcin (OCN) and collagen I, stimulating calcification of the ECM (188). In 
addition to these factors, committed osteoblasts also express bone sialoprotein 
(BSP), osteopontin (OPN) and osteonectin. It has been found that the amount of 
Runx2 bound to the target genes remains relatively unchanged during 
differentiation (189). 
TGF-{31 has divergent actions on bone formation both in vitro and in vivo, 
depending upon experimental conditions, the cells employed, and their stage of 
maturation (190-192). TGF-~1 has been shown either to stimulate or to inhibit 
bone formation and osteoblast markers in vitro (193). In fetal rat calvarial 
osteoblasts, mouse MC3T3 cells, and mouse mesenchymal pluripotent 
C3H1 OT1/2 cells, TGF-~1 inhibits the expression of most of the osteoblastic 
proteins, such as type I collagen, ALP, OCN, and OPN (192, 194). TGF-~1 is 
also produced by osteoclasts and macrophages. 
Additional modulators of osteoblast differentiation are members of 
the FGF family, which act early in skeletogenesis (195). Osterix (Osx) is a 
transcription factor involved in the differentiation of osteoblasts, directing the 
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osteochondroprogenitor cells to the osteoblast lineage (192). Osx _,_embryos 
have hypertrophic cartilage and normal levels of Runx2 (192). Activating 
transcription factor (ATF)-4 controls transcriptional activity in mature osteoblasts 
(196). ATF-4 _,_mice display a mild osteogenesis deficiency phenotype (193-
195). ~-catenin, part of the canonical Wnt signaling pathway, is also implicated 
in the control of chondrocyte and osteoblast differentiation (174, 197-199). 
The process of differentiation can be blocked by specific inhibitors of 
collagen synthesis and integrin-collagen binding (189, 200, 201 ). Inhibition of 
MAPKs, which is a second messenger for these signals, also blocks 
differentiation. Transgenic modification of MAPK causes alterations in 
endochondral bone formation (202). 
1.2.1.2 Osteoblasts produce extracellular matrix 
Osteoblast produce extracellular matrix. Collagen type I is the major 
component of bone matrix and the presence of ascorbic acid (AA) is required for 
its synthesis (203). Osteoblasts contain a specific Na+-dependent AA transport 
system (200, 201 ). AA stimulates procollagen hydroxylation, processing, and 
fibril assembly, followed by induction of OCN, ALP, BSP, and the parathyroid 
hormone-related protein (PTHrP) receptor. AA reduces PI3K-associated signal 
transduction and down-regulates other regulatory kinases, such as Syk, Src, and 
MAPK (204). 
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AA is a general water-soluble anti-oxidant. Accumulating epidemiological 
evidence shows that individuals with low AA intakes have reduced bone mass, a 
greater rate of bone loss, and increased fractures (205-207). Findings from the 
recently reported 17 -year follow-up study of subjects enrolled in the Framingham 
Osteoporosis Study shows that elderly men and women with a dietary history of 
high AA intake have reduced risk of hip fractures of -50% (206). In vivo studies 
suggest that AA deficit induces increased bone resorption. The mechanism for 
this action is increased oxidative stress causing increased osteoclast number 
and activity along with proliferation of dysplastic immature osteoblasts (208). 
1.2.1.3 Osteoblasts modulate the mineralization of extracellular matrix 
Osteoblasts regulate mineralization of the extracellular matrix by precise 
expression of multiple factors. Mineralization occurs by deposition of crystals 
into collagen fibers (209, 21 0). There are several theories for mineralization, the 
most likely being heterogeneous nucleation. This mechanism functions by 
apposition of organic or inorganic particles that direct the formation of apatite 
from soluble inorganic ions. 
One theory proposed that matrix vesicles initiate nucleation, as a 
prerequisite to subsequent mineralization (211-214). According to this theory, 
calcium and phosphate are transported into the interior of the vesicles by 
annexins and Pit-1 ,2, respectively (215, 216). Inside the vesicles, the ions 
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interact with phospholipids to form nucleation complexes and nanocrystals (217-
220). 
Others proposed a mechanism of direct nucleation of apatite by matrix 
macromolecules, especially collagen, and supported by phosphoproteins, 
phospholipids, and proteolipids (221-226). Currently it is accepted that matrix 
vesicles have an important role in regulation of the ratio between P043- and 
inorganic pyrophosphate in the pre-mineralized extracellular space. 
Differentiation signals drive the nuclear translocation of RunX2, followed 
by expression of the mineralization inhibitor OCN (227). In parallel, Runx2 
triggers the expression of ALP, which extracts phosphate from the extracellular 
matrix or from external substrates such as 13-glycerophosphate (BGP). ALP 
localizes to the plasma membrane, with the catalytic domain facing toward the 
extracellular matrix (227-232). 
In MC3T3 cells, ALP activity appeared after 3 days of AA and BGP 
stimulation , and continued to increase for 18-24 days (203). ALP activity was 
found to be correlated with the dose of AA used. ALP mRNA was found in AA-
stimulated cultures supplemented or not with BGP, and peaked at day 16 of 
stimulation with AA. Collagen synthesis inhibitors inhibited ALP mRNA 
expression , as well as its enzymatic activity (203). 
In mouse MC3T3 cells, ALP activity increased until day 24. The increase 
in ALP activity was found to be time-dependent, and not correlated to the initial 
plating density (233) . In contrast to control cultures in which ALP activity 
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remained elevated, in cultures treated with AA and BGP there was a rapid 80% 
decline of ALP activity after 18 days (234). In rat calvaria osteoblasts, ALP 
activity is followed by expression of OCN, discussed below (235). In a different 
study, the activity of ALP from the cytoplasmic fraction of MC3T3 cells peaked at 
10 days and decreased thereafter to less than half the maximum level (236). 
Osteoblasts regulate ion composition of the extracellular space through 
the action of Ca2+ and P043- ion pumps (237, 238). Inorganic phosphate induces 
its own transport via expression of the Pit1 transporter (230) and triggers further 
downregulation of major matrix components, collagen-1a1 and collagen-1a2 
(229, 230). In addition, the phosphate activates gene promoters required for 
mineralization and cell survival through this process (227, 230). When the 
phosphate reaches a critical level, it stimulates the translocation of Runx2 from 
the nucleus, thereby inhibiting OCN expression, resulting in a permissive effect 
on mineralization (231, 232). 
Prevesicle regions form on the cell membrane, containing Pit1 
transporters, ALP, and annexin V Ca2+ channels. The newly-formed osteoid is 
mineralized when phosphate and calcium combine to form crystals of impure 
hydroxyapatite (HA) (Ca10[P04]6[0H]2) in the matrix-bound vesicles (239-243). 
Osteoblasts secrete vesicles and deposit mineral crystals on the osteoid (240, 
244). 
Multiple non-collagenous proteins, including proteoglycans, acidic 
glycosylated, and non-glycosylated proteins associate and regulate bone 
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formation . These proteins provide continuity between the matrix components 
and between the matrix and cellular components. OCN is a small, highly 
conserved acidic protein that regulates mineral maturation (245, 246) and bone 
resorption (247). In MC3T3 cells, OCN mRNA can be detected at day 10 of 
differentiation with AA in MC3T3 cells. Between days 16 and 28 the mRNA 
levels are correlated with formation of bone nodules (236, 248). 
OPN and BSP, the major phosphoproteins in bone, are also expressed by 
osteoblasts. In addition to being highly phosphorylated, these proteins are also 
glycosylated and were found to be implicated in HA binding. Both proteins have 
an arginine-glycine-aspartate (RGD) sequence (249-251) that recognizes the 
vitronectin receptor avf33 (251) through which these proteins mediate cell 
attachment and activate cell signaling pathways (252, 253). OPN and BSP are 
part of the small integrin-binding ligand, N-linked glycoproteins (SIBLING) family 
of proteins (251, 254). The expression of both OPN and BSP is upregulated by 
factors that stimulate bone formation . 
BSP has multiple roles in bone remodeling, and its expression is restricted 
to mineralized tissues. BSP is thought to initialize mineral crystal formation in 
vitro (255) and in vivo (256, 257). High levels of BSP protein in mineralizing 
clones of MC3T3 were found to be correlated to mRNA expression (248). BSP 
induces HA nucleation in vitro (258) and differentiation of pre-osteoblasts (259). 
It also increases bone resorption by osteoclasts (260). BSP is known to attach to 
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both cell membranes (250) and mineral crystals (261) and may serve as an 
adapter between the two. 
OPN, a potent inhibitor of hydroxyapatite crystal growth (262), is enriched 
at all cell-matrix interfaces, where it can mediate the attachment of bone cells 
(263). OPN generally declines prior to osteoblastic differentiation and is 
expressed at high levels after mineralization has been initiated. 
Several factors were shown to enhance mineralization of extracellular 
matrix by osteoblasts in culture: culture media (264, 265), cell density (264, 266), 
the amount of time (267), and media supplementation with organic phosphates 
(268-270). 
1.2.1.4 Innate immune functions of osteoblasts 
Innate immune functions have been attributed to osteoblasts, including 
phagocytosis (271, 272), detection of bacterial products (273, 274), and antigen 
presentation (272 , 275). Bone cells express TLRs, and exposure of osteoblasts 
to bacterial pathogens results in production of cytokines by these cells (276) . 
LPS was found to induce the expression of RANKL in osteoblasts (273, 277). 
TLR activation enhanced osteoclast differentiation by increasing the production 
of TN F-a and RANKL in osteoblasts (273, 278). Osteoblasts may also mediate 
the development of an immune response, by releasing inflammatory cytokines 
and recruiting leukocytes to sites of bacterial challenge. 
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Osteoblasts are also involved in hematopoiesis, and evidence shows that 
chemical ablation of osteoblasts impairs this process (279). In addition, specific 
interactions occur between osteoblasts and hematopoietic stem cells (HSC) 
(280-282). Several cell surface receptors , cytokines and signaling pathways are 
utilized both in the immune and bone systems (see section 1.2.7 below). 
1.2.1.5 Mouse MC3T3 cells are important osteoblast models 
The MC3T3 are a well-characterized murine osteoblast cells line. The 
behavior of MC3T3 cells is similar to primary calvarial osteoblasts. These cells 
form a well-mineralized extracellular matrix after 10 days (248). In MC3T3 cells, 
the temporal expression sequence of the genes encoding the osteoblast markers 
follows the specific pattern of gene expression of long bone and fetal calvarial 
cells (233, 283). 
Upon supplementation with the osteogenic media containing ascorbic acid 
and ~-glycerophosphate , the osteoblast culture undergoes three stages: 
1. Proliferation followed by growth arrest (days 0-1 0). 
2. Differentiation of preosteoblasts into osteoblasts and expression of mature 
osteoblastic characteristics: matrix production and maturation (days 10-21 ). 
3. Formation of multilayered nodules with a mineralized extracellular matrix 
(after day 25) (Fig. 4) . 
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Figure 4 - Stages of osteoblast culture. 








Weeks in culture 
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Figure 4- Stages of osteoblast culture. Proliferation, matrix formation, and 
mineralization are shown as function of time. Cells cultured in osteogenic media 
proliferate, differentiate and produce bone extracellular matrix, and finally 
mineralize this matrix. Col I - Collagen type I. FN - Fibronectin. OCN -
Osteocalcin. OPN- Osteopontin. 
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1.2.2 The RANKL:OPG ratio determines bone remodeling 
RANKL is part of the TNF-family of cytokines (284, 285) and is expressed 
by osteoblasts in response to PGE2, PTH, and 1 ,25-dihydroxyvitamin D3. 
RANKL is a crucial determinant of the level of bone resorption in vivo , due to its 
function in osteoclast differentiation (192). It is expressed also by activated T-
cells, indicating that osteoclasts can be directly activated by the immune system 
(286, 287). In co-culture of mouse MC3T3-E1 cells and bone marrow cells it was 
found that osteoblast differentiation inhibits osteoclastogenesis (288). RANKL 
and macrophage colony-stimulating factor (M-CSF) mRNA decrease during 
differentiation (285). 
RANKL is expressed in both soluble (289-291) and membrane-bound 
forms (292, 293). The precise contribution of each of the two RANKL forms in 
physiological and pathological conditions has not been characterized. 
RANKL activates RANK, a receptor that lacks enzymatic activity in its 
intracellular domain . RANK transduces the signal by recruiting adaptor 
molecules such as the TNF-receptor-associated factor (TRAF) family of proteins 
(284), from which TRAF-6 appears to be the main mediator (294-296). RANKL 
binding to RANK induces the trimerization of RANK and TRAF6, leading to 
activation of NF-kB and MAPKs, including JUN N-terminal kinase (JNK) and p38 
(297). 
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TLRs use TRAF6 as part of their signaling cascade (13). RANK also 
activates the transcription factor complex activator protein 1 (AP1 ), through 
induction of its component cFOS (298). In addition, RANK cooperates with other 
receptors: osteoclast-associated receptor (OSCAR) and a triggering receptor 
expressed on myeloid cells (TREM-2) (299-301). RANKL specifically induces 
nuclear factor of activated T cells, cytoplasmic 1 (NFATc1), in a TRAF6-NF-kB-
and cFOS-dependent fashion. 
Osteoprotegerin (OPG), member of the TNF receptor family, is a 
homodimeric secreted protein expressed in osteoblasts (302, 303). OPG-
deficient mice develop severe early-onset osteoporosis with increased osteoclast 
numbers (304, 305). Serum OPG levels increase with age (306), pregnancy 
(307), and cardiovascular disease (308), and decrease in multiple myeloma 
(309). Overexpression of OPG in transgenic mice resulted in osteopetrosis due 
to failure of osteoclast formation (31 0). It is widely accepted that the RANKL-
OPG ratio is important to the regulation of bone resorption at the cellular level 
(310). Fish oil supplementation was found to decrease sRANKLIOPG in patients 
with rheumatoid arthritis (311). 
OPG inhibits osteoclast formation at a late stage of their development 
(302, 303, 312-314). In vitro , OPG was shown to function as a decoy receptor 
for RANKL, tightly binding the N-terminal cystein-rich domain (315, 316). OPG 
secretion was found to be initiated by activation of the protein-kinase C pathway 
in sarcoma osteogenic (SaOS)-2 cells (317). PGE2 was found to inhibit OPG 
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expression through the protein-kinase A pathway in bone marrow cells (318). 
PTH inhibits OPG through stimulation of cAMP accumulation (319) . The 
expression of OPG mRNA was shown to be stimulated by TGF-13 possibly 
through interactions of Runx2 and SMAD (320). Proper transfer of RANKL from 
the Golgi apparatus to the secretory lysosomes was found to be associated with 
co-expression of OPG (321 ). 
1.2.3 Osteocyte function in bone metabolism 
Osteocytes are the most abundant cells in bone. They originate as 
osteoblasts that become incorporated in the matrix. At this stage, the cells 
generate long cytoplasmic processes that allow communication with surrounding 
cells and upregulate the expression of E11, an early osteocyte marker (322). 
These cells further mature and express dentin matrix protein-1 (DMP-1 ), matrix 
extracellular phosphoglycoprotein (MEPE), and sclerostin (SOST) (262, 263, 
322-324), becoming osteocytes. 
Osteocytes respond indirectly to extracellular fluid flow caused by loading 
but do not respond directly to mechanical forces. In culture, fluid shear stress 
causes the release of.several messengers, including prostaglandins and nitric 
oxide (286). New evidence shows high expression of RANKL in osteocytes, 
which appears to have a greater impact on osteoclastogenesis than osteoblasts 
or bone marrow stromal cells (325). 
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1.2.4 Osteoclasts resorb bone extracellular matrix 
Osteoclasts are specialized multinucleated cells that resorb bone matrix. 
They originate from preosteoclasts, derived from mononuclear cells generated 
from hematopoietic stem cells. Committed preosteoclasts are introduced into the 
blood stream or function locally in the bone marrow. Osteoclast differentiation is 
regulated by M-CSF and RANKL (285). M-CSF is thought to be important for the 
proliferation of the osteoclast progenitors. 
The survival of mature osteoclasts is modulated by multiple factors 
such as IL-1, RANKL, TNF-a, and M-CSF (326-328). In post-menopausal 
women, estrogen loss is associated with elevated bone resorption caused by a 
rise in osteoclast number due to increases in IL-6 (329), IL-11, and PGE2 , in 
addition to the factors mentioned above. Several intracellular molecules were 
proven to be necessary for the survival of osteoclasts: MAPK (330, 331 ), NF-kB 
(332) and PI3K (330, 333). 
1.2.5 Osteal macrophages are bone resident cells of the immune system 
Osteal macrophages are resident cells whose anatomical location 
suggests a physiological rather than an immunological function. Resident 
macrophages function in other tissues and are required for ductal outgrowth in 
the development of mammary glands (334) and for development of 13 cells in the 
pancreas (335, 336). In the skin resident macrophages are associated with 
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fibrosis (337). Following IL-4 release, which is one of the first signals of tissue 
injury (338), resident macrophages become promoters of wound healing (18) . 
These cells can have regulatory effects on neighboring cells (339, 340). They 
were defined as CCRZCX3CR1hiGRr (341). 
Macrophages were described as components of the bone tissue (342) . A 
recent study found that a population of mature F4/80+ macrophages was co-
isolated with primary calvarial osteoblasts. In situ, resident macrophages were 
found to be closely associated with areas of bone remodeling. The same study 
also found that these macrophages contribute specifically to osteoblast 
maturation and mineralization. Calvarial osteoblast cultures from which 
macrophages were removed expressed lower levels of OCN mRNA and 
produced less mineral. Depletion of F4/80+ in vivo resulted in loss of the 
osteoblast bone surface (343). Although immunological functions have been 
attributed to them, primary osteoblasts do not express all of the receptor 
components required for responding to pathophysiological levels of LPS (343). 
Macrophages are cellular components of the bone marrow, and evidence 
shows their involvement in the regulation of bone function. These cells 
contribute to resolution of inflammation by withdrawal of survival signals, 
normalization of chemokine gradients, and by induction of resolution programs 
that decrease the presence of the infiltrating cells (344). High molecular weight 
hyaluronan acts on macrophages to decrease osteoclast differentiation, while low 
molecular weight hyaluronan stimulates differentiation (345, 346). 
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The F4/80 antigen is part of an integral membrane protein called emr1 , 
which is a GPCR of unknown function that has extracellular EGF and mucin-like 
repeats (347, 348). Osteoclasts lack detectable F4/80, and loss of this antigen is 
a useful marker for their divergence from macrophages (349). F4/80+ 
macrophages are distributed throughout the endosteal, periosteal, and 
perivascular surfaces of bone. 
Co-culture of macrophages with osteoblast-like calcifying vascular cells 
resulted in increased ALP expression and matrix mineralization by these cells 
(58). Production of TN F-a was discovered to be the mediator of this action. In 
osteoarthritis models, depletion of macrophages reduced pathologic bone 
formation (59, 350, 351 ). Macrophages were also found to be associated with 
sites of pathologic bone loss (61, 352) and to contribute to pathologic 
mechanisms in an animal model of osteoporosis (353). Macrophages can 
potentially regulate bone function by expression and secretion of cytokines, 
MMPs and BMPs (59-61 ). 
In spite of the fact that bone marrow macrophages and rheumatoid 
synovium-derived macrophages can be differentiated into osteoclasts in vitro, 
there are more primitive, alternative myeloid cells in the bone tissue that can be 
more efficiently differentiated into osteoclasts (354, 355). Osteal macrophages 
produce TNF-a (356, 357), IL-1 (357, 358), IL-6 (359) or IFN-13 (360, 361) , which 
can modulate the differentiation and function of osteoclasts. 
51 
In bone tissue, osteoclasts function at the leading edge of the formation 
phase. They initiate the recruitment, proliferation, and initial differentiation of pre-
osteoblasts (362). Osteoclasis move on or become apoptotic before the 
formation is completed, and the hypothesis is that at this stage, macrophages 
stimulate osteoblasts to produce matrix and to mineralize it. The production of 
M-CSF by osteoblasts results in stimulation of macrophage proliferation, which 
leads to further mineralization signals to osteoblasts (363) . 
Macrophages secrete factors that can modulate osteoblast differentiation 
and function: OPN (364) , vitamin 0 3 (365), and BMP-2 (60), increasing the 
population of osteoblast precursors, the proliferation of bone lining cells and their 
attachment to bone surface. TGF-~ (366) and ephrin 82 (367, 368), expressed 
by osteoclasts and macrophages, are additional signals for bone formation. 
Depletion of macrophages from calvaria cultures compromises maturation of 
osteoblasts, whereas depletion in a transgenic mouse model causes a decrease 
in osteoblast bone modeling surface (343). 
In response to signals from macrophages that are exposed to 
inflammatory stimuli, osteoblasts increase their production of PGE2 (267, 369, 
370) , which leads to bone resorption (370, 371 ). These facts support the findings 
of osteopenia and osteoporosis in states of inflammation (372, 373) and systemic 
infection (374, 375). 
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1.2.6 Factors that regulate bone tissue function 
1.2.6.1 Polyunsaturated fatty acids (PUFA) function in bone remodeling 
Evidence shows that COX-2 plays an essential role in endochondral and 
intramembranous bone remodeling during skeletal repair (73-75). 
Prostaglandins of the E series stimulate bone resorption and bone formation in 
vitro and in vivo. In bone organ culture (376-378) and co-cultures of primary 
osteoblasts and osteoclast precursor cells (73, 379) , PGE2 was found to act on 
osteoblasts in an autocrine fashion, triggering osteoclast recruitment and causing 
bone resorption. 
Cytokines, growth factors, and hormones modulate PGE2 production in 
mouse osteoblasts. In these cells, IL-1 and IL-6 increase bone resorption (380) , 
whereas IL-4 (381, 382) and IL-13 (382) decrease it by inhibiting COX2-
dependent PGE2 production. The production of IL-6 itself depends on the 
cellular stage of differentiation and the responsiveness to PGE2 (383). In primary 
rat calvarial osteoblast cultures (76, 77) and MC3T3 cells (78) , PGE2 stimulates 
mineralization and activity of ALP. COX2 expression is induced in response to 
fluid sheer stress in osteoblasts (384) due to activation of Runx2 through the 
MAPK pathway (243, 385) . 
PGE2 and COX2 were found to be increased in fracture regions (79, 80) 
and fracture healing was found to be delayed in COX2-deficient mice relative to 
COX1 deficient mice or wildtypes (75). Mechanical stress, which is necessary for 
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fracture healing, is mediated by PGE2 and COX2 (81-83). In ovariectomized rats, 
administration of PGE2 suppresses bone loss (386-388). However, endogenous 
PGE2 was found to stimulate bone resorption in osteoporotic animals (389, 390) 
and humans (391-393). In humans, bone mineral density (BMD) was found to 
increase upon treatment with NSAIDs. 
PGE2 appears to be involved in several bone-resorptive inflammatory 
disorders. In rheumatoid arthritis, PGE2 is possibly involved in joint destruction. 
In these patients, the expression of mPGES-1 in synovial fibroblasts rises in 
response to TNF-a and IL-1J3 (394). In mouse models, knockout of mPGES-1 
reduced disease severity compared to wild-type controls (395, 396). In 
osteoarthritis, PGE2 was found responsible for worsening the loss of articular 
cartilage (397 -399). The PGE2 concentration in the crevicular fluid is increased 
in periodontitis patients (400). 
There have been four receptors identified: EP1-4 (66). Studies in PGE2 
EP 4 and EP2 receptor knockout mice show imbalances in bone remodeling due 
to deficiencies in bone formation , reduced structural strength , and reduced 
trabecular bone volume (401-403). LPS induction of bone resorption is reduced 
in cPLA2a-, mPGES-1-, and EP 4-deficient mice (404-406). The effects of other 
prostanoids such as PGb, PGF2a, PGE1 , PGD2 and TxA2 on bone remodeling 
are less defined. 
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1.2.6.2 Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), w-3 
fatty acids, function in bone remodeling 
Consumption of w-3 fatty acids rich in EPA, DHA, and gamma-linolenic 
acid (GLA) has been associated with reduced resorption of bone in both animal 
(1 07) and human studies (1 08, 1 09). In a rabbit model of periodontal disease, 
RvE1, a derivative of EPA, induced regeneration, not only due to inhibition of 
resorption, but also due to enhancement of bone formation (1 ). 
Clinical trials with fish oil for the treatment of rheumatoid arthritis show 
amelioration of the clinical symptoms (407 -411 ). In arthritis-prone mice, a fish 
oil-supplemented diet maintained a higher bone mineral density than a corn oil-
based one (412). In ovariectomized mice, a fish oil diet was found to be 
protective against decrease of bone mineral bone density (1 09). 
In rats infected with Porphyromonas gingiva/is, a gram-negative and 
anaerobic bacterium, w-3 fatty acid-rich diet inhibited the expression of pro-
inflammatory cytokines TN F-a and IL-1 ~.decreasing alveolar bone resorption. In 
addition, the w-3 fatty acid diet enhanced IFN-y, catalase, and superoxide 
dismutase mRNA expression (413). 
The three major lipoxygenases, known to participate in resolvin 
biosynthesis, were shown to be expressed in human bone cells . The expression 
of 12-LO and 15-LO type 2 appears to be regulated by PTH, with 12-LO being 
stimulated and 15-LO suppressed (414). The gene Alox 15 was found to encode 
the 12/15-lipoxygenase (12/15-LO). 12/15-LO stimulated adipogenesis in 
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marrow-derived mesenchymal progenitors by converting arachidonic and 
linolenic acid into endogenous ligands for peroxisome proliferator-activated 
receptor (PPAR)-y (415-417). In calvarial cell cultures, increased Alox15 
expression causes a reduction in OCN (415). An autosomal genome screen for 
spinal BMD, found a linkage between osteopenia and a chromosomal region 
containing the genes encoding human 12-LO and 15-LO (418). In addition, a 
single nucleotide polymorphism of PPAR-y was found associated to BMD in post-
menopausal women (419). 
1.2.6.3 The pro-inflammatory cytokines TNF-a and IL-6 function in bone 
remodeling 
TNF-a is a central mediator of responses to endotoxin, rheumatoid 
diseases, and other forms of inflammation. TN F-a is produced by fibroblasts, 
osteoblasts, smooth muscle cells (420, 421), infiltrating leukocytes, and activated 
macrophages (422 , 423). The effect of TN F-a depends on the cell type and 
culture conditions (424-428). 
TNF-a is a non-glycosylated protein of 17kD, whose actions are mediated 
by the specific receptors type I (p55/p60) and II (p75) . The inflammatory 
response triggered by TN F-a induces production of inflammatory cytokines, such 
as interleukins, IFN-y, and chemokines. NF-kB, a survival factor, mediates TNF-
a response following its nuclear translocation (429, 430). Different stimuli 
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activate different gene expression programs using the same IKK-IkB-NF-kB 
signaling module. 
TNF-a has multiple functions in bone metabolism. In addition to 
stimulation of osteoclast differentiation and function, it inhibits osteoblast 
differentiation and induces the production of inflammatory factors (27 -29), 
RANKL, and M-CSF by these cells (431), possibly through NF-kB (432) (Fig. 5). 
In spite of its bone resorptive functions, however, TN F-a was found to be 
important for initiating osteogenesis (433). 
RvE1 was found to inhibit TNF-a-induced NF-kB activation in ChemR23-
transfected human embryonic kidney (HEK)-293 cells in a dose-dependent 
manner (100), suggesting that a similar mechanism may function in osteoblasts. 
IL-6 is a major proinflammatory cytokine that regulates osteoclastic bone 
resorption and has been implicated in the pathogenesis of several bone diseases 
(39). IL-6 and the soluble IL-6 receptor (sll-6R) are expressed in bone marrow 
osteoblasts in vivo (434-436). IL-6 has been shown to decrease OCN 
expression in osteoblasts (437) and to inhibit bone formation in vitro (438). IL-6 
exerts differentiation stage-dependent effects on proliferation, maturation, and 
apoptosis (29, 439). IL-6 must be combined with sll-6R in order for bone 
resorption to occur (440). 
IL-6 has no detectable effects on RANKL production in MC3T3 cells. In 
spite of the fact that IL-6 has no direct effects on OPG production, IL-6 
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neutralizing antibodies increased OPG secretion. IL-6 increased the expression 
of EP2 and EP4 receptors in MC3T3 cells (441). However, co-stimulation of 
osteoblasts with IL-6 and sll-6R increased RANKL and OPG mRNA expression 
and protein synthesis (440). 
Although high IL-6 levels stimulate bone resorption, physiologic levels can 
do so only in the presence of other cytokines (442, 443). TN F-a, IL-1, and IL-6 
stimulate bone resorption in a synergistic fashion (444), resulting in a net 
increase in RANKL expression. In epithelial cells, IL-6 was shown to increase 
the mRNA expression of the ChemR23 receptor by 40% (142). 
IL-6 signals through gp130 in both osteoblasts and osteoclasts. 
Formation of the gp130 complex results in activation of cytoplasmic Janus 
kinases (445), signal transducer and activator of transcription (STAT) 1 and 
STAT3 (446, 447), and the SHP2/ras/MAPK (448) signaling pathways. IL-6 
stimulates osteoblast differentiation through the STAT1/3 pathway (449). The 
gp130-SHP2/ras/MAPK pathway inhibits osteoclastogenesis. Inhibition of the 
gp130 pathways in knockout mice models resulted in increased osteoclast 
numbers and bone resorption, but also increased bone formation (450, 451 ). 
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Figure 5 - Multiple functions of TNF-a in the bone tissue. 
Stimulation of production of RANKL 
and M-CSF in osteoblasts 






Figure 5- Multiple functions of TN F-a in the bone tissue. TN F-a acts directly on 
osteoclasts, stimulating differentiation and function, and indirectly by stimulating 
production of RANKL and M-CSF by·osteoblasts. TNF-a also inhibits osteoblast 
differentiation. 
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1.2.7 The process of bone repair 
The action of the bone cells and mediators determines the function of 
bone in health and pathological conditions. Bone trauma leads to various 
degrees of interruption of blood supply to bone and adjacent soft tissues (452). 
In compact bone, initiation of bone repair activates cellular programs that occur 
during embryonic bone formation. Trauma initiates an inflammatory phase (453, 
454), consisting of cellular migration and proliferation, directed by growth factors 
released from the ECM (455). Blood vessel disruption leads to the formation of 
hematoma, its fibrin fibers acting as a scaffold for cell proliferation. Leukocytes 
and bone marrow cells accumulate and a blood clot forms between and around 
the fracture ends (456). Stem cells are mobilized, initiating chondrogenesis, and 
ingrowth and new formation of blood vessels. 
Multiple cellular mediators coordinate the inflammatory response and 
subsequent mineralized tissue formation: pro-inflammatory cytokines (IL-1, IL-6, 
IL-11, IL-18 and TN F-a), angiogenic factors, and members of the TGF-~ 
superfamily (457). This brief secretion of pro-inflammatory mediators is critical 
for tissue regeneration (456). This acute response has been shown to peak 24h 
after the fracture and to resolve after 7 days. 
TNF-a, which is produced mainly by macrophages, was found to increase 
at 24h and to return to baseline within 72h after the fracture (456) . TN F-a has 
multiple roles in bone healing, including induction of mesenchymal stem cell 
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(MSC) differentiation (458), induction of secondary inflammatory signals, and 
chemotaxis of inflammatory cells (459). The expression of IL-1 by macrophages 
overlaps with that of TN F-a. IL-1 has multiple roles in fracture healing: 
angiogenesis, induction of IL-6 in osteoblasts, and promotion of formation of a 
primary cartilaginous callus (459, 460). 
Chondrocytes proliferate in the cartilaginous callus, after which they 
become hypertrophic, and the ECM that they produce is mineralized. This 
mineralized callus is resorbed upon stimulation by M-CSF, RANKL, OPG and 
TNF-a (456, 461). 
In addition to recruitment of osteoblast progenitors from the surrounding 
tissues and the bone marrow, circulating MSCs are also required for optimal 
fracture healing (462, 463) . . The periosteum has an important role in this process 
of repair as a source of precursor cells and blood supply. Edema, vessel 
ingrowth, and cell proliferation combine to cause separation of muscle fibers 
resulting in local swelling. Under the regulation of local factors , mesenchymal 
cells in the periosteum and other pluripotent cells between the muscle fibers and 
around the blood vessels differentiate into osteoblasts, chondroblasts, or 
fibroblasts, (464) . 
The formation of new blood vessels is mediated by angiopoietin- and 
VEGF-dependent pathways (465). The angiopoietins are vascular 
morphogenetic proteins that are induced early in the healing cascade (466). The 
key regulator of vascular regeneration is the VEGF pathway (467). 
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Osteoblasts produce osteoid, which is an unmineralized extracellular 
matrix. The formation of osteoid is independent of mechanical factors. This new 
matrix consists of randomly arranged collagen fibers of collagen type I, which 
subsequently mineralize, creating the woven bone. The initiation of bone 
formation is mediated by BMP-2. Other members of the TGF-~ superfamily, 
TGF-~2 , -~3 and growth I differentiation factor (GDF)-5 mediate chondrogenesis 
and endochondral ossification , whereas BMP-5 and -6 induce cell proliferation in 
processes of intramembranous ossification (458, 468). M-CSF, RANKL and 
OPG are also involved in the production of new bone. 
Woven bone is next remodeled into lamellar bone, forming a primary 
bridging callus. The original anchoring callus develops into a bridging callus , 
which is comprised of bone or fibrocartilage, and is covered by a fibrous layer 
identical to the fibrous layer of the periosteum. The replacement of fibrocartilage 
by bone is known as endochondral or indirect bone formation . Cells from the 
bridging callus or from the marrow invade the gap between the fragments 
forming the uniting callus (453). 
Callus formation is controlled by signals transduced by functional , cyclic 
loading from the bone and soft tissues. This primary bone is later remodeled into 
secondary bone in order to restore load-bearing function (456) . In membranous 
bone, formation occurs directly from the mesenchyme. 
Osteoblasts are widely viewed as the orchestrators of bone remodeling , 
however evidence shows the involvement of bone macrophage resident cells in 
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this process (469). Macrophages are present during multiple stages of fracture 
repair. These cells produce mesenchymal growth factors at the fracture site 
(470) and have been associated with more stable callus formation (471). 
Both osteoblasts and hypertrophic chondrocytes express elevated levels 
of VEGF, thereby promoting the formation of blood vessels, and the 
transformation of the avascular cartilaginous matrix into a vascularized 
mineralized tissue (467). IL-1, TN F-a, and BMP-2 mediate a second resorptive 
phase, in which the hard callus is remodeled into lamellar bone with a central 
medullar cavity (456). 
In order to obtain complete fracture healing, it is necessary to develop an 
adequate blood supply and a gradual increase in mechanical stability (472). 
Similar to wound repair, complete regeneration of bone function requires an 
orchestrated function of multiple cellular and biochemical processes. In addition, 
these bone healing processes occur in the context of endocrine and immune 
regulation, which determine the regeneration of the bone tissue. 
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Hypothesis 
Previous work has demonstrated that inflammatory bone loss induced by 
infection can be reversed by topical application of resolvin E1 (RvE1 ), ·leading to 
bone regeneration (1 ). New bone formation requires osteoblasts. The question 
to be addressed is the relationship of resolution of inflammation to bone 
formation . The resolution agonist, RvE1, was shown to directly bind to and 
inhibit osteoclast activation; however, inhibition of bone resorption does not 
entirely account for new bone formation and an increase in osteoblasts was also 
noted (unpublished observation). The hypothesis to be tested is that RvE1 acts 




The goal of the project is to determine the impact of RvE1 on osteoblast-
mediated bone formation and to define the mechanism of action. 
Aim 1- Establish the actions of RvE1 in a bone healing model (mouse 
craniotomy) . 
a. Does RvE1 increase bone healing? 
b. Does over-expression of a receptor for RvE1 in a transgenic animal 
enhance healing? 
Aim 2- Determine the mechanism of action of RvE1 on bone marrow 
macrophages in vitro. 
a. Is ChemR23 expressed in bone marrow macrophages? 
b. Does RvE1 alter the production of mineralized matrix by osteoblasts 
indirectly through macrophages? 
c. Is macrophage signaling to osteoblasts altered by inflammatory 
stimuli? 
Aim 3- Determine the mechanism of action of RvE1 on osteoblasts in vitro. 
a. Do isolated calvaria cells express an osteoblast phenotype? 
b. Is the ChemR23 receptor expressed in calvaria osteoblasts? 
c. Does RvE1 regulate osteoblast differentiation? 
d. What functions of osteoblasts are regulated by RvE 1? 
e. Does RvE1 alter intracellular pathways in osteoblasts? 
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f. Does RvE1 regulate OPG expression in osteoblasts stimulated with IL-
6? 
3 Methods 
3.1 Mouse model 
The experiment was performed under the approval of the Institutional 
Animal Care and Use Committee (IACUC protocol# 14615). FVB and Balb/c 
mice were purchased from Charles River Laboratories (Wilmington, MA). All 
animals received standard chow diet and water ad libitum. Mice were 
anesthetized using a mixture of Ketamine I Xylazine and the fur in the surgical 
area was trimmed and aseptically prepared. A longitudinal incision was made in 
the center of the scalp. Periosteum was removed in a small area in the parietal 
region. A 1 mm craniotomy was created using a round carbide dental bur at 
2000 rpm under saline irrigation (473). The incision was sutured and the mice 
received an analgesic every day for 3 days. 100 ng RvE1 diluted in 10 1-11 PBS or 
ethanol diluted in 10 1-11 PBS was injected into the wound area every 2 days under 
isofluorane sedation. Mice were sacrificed after 14 days by C02 asphyxiation . 
3.2 Histology 
Calvaria from the operated mice were isolated, washed in deionized 
water, and then incubated overnight in 4% formaldehyde in PBS. Calvaria were 
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then incubated in 70% ethanol and embedded in paraffin as previously reported 
(473). 6 1-1m coronal sections of the parietal bone were prepared through the 
center of the circular defect (Microm HM 360 microtome, Walldorf, Germany), 
and then stained with hematoxylin-eosin (H&E). Briefly, sections were 
deparaffinized and hydrated in sequential incubations with 100% xylene and 
decreasing concentrations (1 00, 95, and 70%) of ethanol. Sections were stained 
in Harris hematoxylin for 1 min, counter-stained with eosin for 20 sec, incubated 
with 0.015 N hydrochloric acid followed by 0.45% ammonia, after which the 
slides were dehydrated in increasing concentrations (70, 95 and 1 00%) of 
ethanol and xylene and cover-slipped using Permount (Fisher Scientific). 
For tartrate-resistant acid phosphatase (TRAP) staining, slides were 
deparaffinized and hydrated as described above and incubated in 0.2 M Tris 
buffer (pH 9.0) for 1 h at 3rC, rinsed in deionized water, then incubated in 
acetate buffer (0.2 M, pH 5.0) for 20 min at room temperature. Staining solution 
was prepared by mixing 25 mg naphthol AS-TR (Sigma), 55 mg Fast Red TR 
(Sigma), 0.58 g tartaric acid (Sigma) , 25 ml Tris acetate buffer 0.2 M, pH 5.0 and 
23.6 ml deionized water. Slides were incubated in the staining solution for 40 
min at 3rC, and then rinsed three times with tap water, counterstained with 
Harris' hematoxylin for 5 sec, followed by tap water for 1 min , air-dried and cover-
slipped using Permount. 
Slides were examined by light microscopy (Zeiss Axiovert 200, Carl Zeiss, 
Heidelberg , Germany). Images were captured using a microscope-interfaced 
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camera (Sony DFW-X?OO, Sony Corp., Tokyo, Japan) and analyzed (MicroSuite, 
Olympus America, Inc., Melville, NY). 
3.3 Cells 
Bone marrow macrophages, MC3T3 cells, bone marrow osteoblasts, and 
calvarial osteoblasts were the cells of choice to study the action of RvE 1 on 
macrophage and osteoblast function. Cells were incubated at 3rC, 5% C02 in 
humidified atmospheric conditions. 
3.3.1 Bone marrow macrophages (BMM) 
BMM were isolated by flushing the marrow cavities from 6-8 week old FVB 
mouse femurs with RPMI medium (Invitrogen) supplemented with 10,000 IU 
penicillin, 10,000 IJg/mL streptomycin (Fisher), 10% fetal bovine serum (FBS) 
(ATCC). 4 x 106 cells were plated in 10 em Petri dishes in media supplemented 
with 30 ng/ml M-CSF (Peprotech). After 3 days, 5 ml fresh supplemented 
medium was added. Cells were passaged on day 7 using cell scrapers (Fisher). 
For the experiments, 8 x 105 cells were plated in 24-well plates in RPM I 
supplemented with 30 ng/ml M-CSF. After one day, medium was replaced with 
fresh medium and stimulation performed (sections 3.2.3, 3.2.4) . 
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3.3.2 MC3T3 cells 
The MC3T3 cell line is a pre-osteoblast cell line derived from murine 
calvaria cells. In the logarithmic phase, the cells have a fibroblastic morphology 
and very low ALP activity. After growth to confluence, the cells continue to grow 
slowly and form multiple cell layers (267). 
Following stimulation with ascorbic acid (AA) and 13-glycerophosphate 
(BGP), these cells differentiate into functional osteoblasts, secreting osteoblast-
specific markers and producing mineralized extracellular matrix (248, 474). 
Proa2(1) collagen subunit mRNA was found to be expressed at high levels in 
MC3T3 cells, and increased upon AA stimulation (248). Other studies however, 
found collagen mRNA levels to be independent of AA and BGP supplementation 
(233). 
We used MC3T3 cells subclone 4 of passage 8-10. MC3T3 cells were 
cultured in a-M EM medium with ribonucleosides or deoxyribonucleosides 
(Invitrogen) , 10,000 IU penicillin, 10,000 IJg/ml streptomycin and 10% FBS. To 
support differentiation, media were supplemented with 50 IJg/ml AA and 10 mM 
BGP and changed every other day. 
3.3.3 Bone marrow osteoblasts 
Bone marrow cells are a heterogeneous population of hematopoietic and 
fibroblast-like cells of the marrow stroma. Stromal cells can be bi-potent, multi-
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potent, or cells committed to restricted lineages such as osteoprogenitors and 
pre-adipocytes. These cells are useful in the study of the sequential expression 
of markers during osteoblast differentiation (475-478). Differentiation of bone 
marrow cells in vitro is induced with AA, BGP, and dexamethasone (479). BGP 
supports the formation of extracellular mineralized nodules. Culture in this 
supplemented media is known to generate cell populations that form mineralized 
nodules, express bone markers, and produce ALP in a manner consistent with 
an osteoblast phenotype (268, 480, 481). 
Bone marrow osteoblasts were isolated from femurs of FVB mice. 6-8 
weeks old mice were euthanized using C02, and hind legs were aseptically 
removed by dissection. The marrow cavities of both femur and tibia were flushed 
with a-MEM medium supplemented with 10% FBS, 10,000 IU penicillin , and 
10,000 IJg/ml streptomycin using a 10 ml syringe with 25G needle. Extracts were 
centrifuged at 300 x g for 10 min. Pelleted cells were plated at 106 cells/well in 6-
well plates. Half of the medium volume was changed on day 4. On day 6, the 
media were changed to osteoinductive media, containing 50 IJg/ml AA, 10 mM 
BGP and 1 o-s M dexamethasone. After day 6, media were changed every other 
day for the remainder of the experiment. 
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3.3.4 Calvarial osteoblasts 
Osteoblast development and differentiation is characterized by marked 
intercellular heterogeneity in gene expression in vitro as well as in vivo. 
Osteoblast markers are differentially expressed in cells that originate from 
various maturational states, ages, and environments. In addition, the state of the 
cells determines the action of growth and differentiation factors (482). In order to 
provide a homogenous cell population that is consistent with and complements 
the calvarial healing experiments, neonatal mouse calvaria-derived osteoblasts 
were used in a number of experiments. 
Neonatal mice calvarial osteoblasts were isolated from mouse litters (7 -8 
mice, 2-4 days old) by dissection of the scalp skin and removal of the calvaria. 
Calvaria were incubated in a-M EM medium supplemented with 10% FBS, 10,000 
IU penicillin, and 1 0,0001Jg/ml streptomycin and then incubated for 10 min at 
3rC in a 4mM Na2- ethylenediaminetetraacetic acid (EDTA) solution 3 times in 
order to demineralize the extracellular matrix; the supernatants were discarded. 
The calvaria were then incubated twice at 3rC in a freshly prepared collagenase 
type 2 solution (Worthington) in 137 mM NaCI, 2.7 mM KCI, 3 mM NaH2P04 x 
H20 on an orbital shaker to separate the cells from the extracellular matrix; the 
first 2 supernatants were discarded. The digests from the following five 
sequential incubations with collagenase were pooled, centrifuged, and 
resuspended in a-M EM media supplemented with 10% FBS, 10,000 IU penicillin, 
10,000 1-1g/ml streptomycin. 5 x 105 cells were plated in 75 ml flasks and when 
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reaching 90% confluence, cells were passaged into 12 well-plates at a density of 
4 x 1 04 cells/well for RNA isolation and into 24-well plates at a density of 2 x 1 04 
cell/well for Alizarin Red staining. Media were changed every other day. 
3.4 Flow cytometry 
Macrophages were cultured in 10 em Petri dishes in RPM I supplemented 
with 10% FBS, 10,000 IU penicillin, 10,000 jJg/ml streptomycin, and 30 ng/ml M-
GSF. FAGS was used to detect F4/80 antigens, specific for macrophages, and 
GhemR23. Adherent cells were isolated by scraping using cell lifters, and 
incubated on ice. FAGS buffer was prepared by mixing PBS, 0.2% sodium azide 
and 5% FBS. Following 5 min centrifugation at 4 oG at 300 x g, the supernatant 
was discarded, and the cells were incubated for 10 min in 4% formalin in PBS pH 
7.4 on ice. PBS was added and the cells were centrifuged for 5 min at 4°G at 
300 x g. The supernatant was discarded and the cells were incubated with 
antibody solution for 60 min on ice in the dark. The antibodies used were: 
fluorescein isothiocyanate (FITG)-conjugated rat anti-mouse F4/80 
(eBioscience), lgG 2a-FITG (eBioscience) as isotype-matched control, 
phycoerythrin (PE)-conjugated rat anti-mouse ChemR23 (eBioscience) , with lgG 
2a-PE as isotype-matched control. Antibodies were added in FAGS buffer for 60 
min and the cells were centrifuged for 5 min at4°C at 300 x g. The supernatant 
was discarded and the cells were incubated on ice in FAGS buffer. Fluorescence 
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levels from 10,000 events were measured using a BD FACScan with BD 
Cellquest Pro v5.2 software (BU Flow Cytometry Core Facility). The results are 
presented as histograms with fluorescence intensity on the x-axis and number of 
cells ('events') on the y-axis. , 
3.5 Calcium assay 
BMM were differentiated in RPM I media supplemented with 10% FBS, 10,000 IU 
penicillin, 10,000 IJg/ml streptomycin , and 30 ng/ml M-CSF. At confluence 2 x 
1 05 cells were passaged onto inserts and incubated in 24-well plates. MC3T3 
cells were cultured at the bottom of the wells in these 24-well plates at a density 
of 2 x 104 cells/well in a-M EM with 10% FBS, 10,000 IU penicillin, 10,000 IJg/ml 
streptomycin, 50 IJg/ml AA and 10 mM BGP. Media were changed every other 
day. 
Calcium concentration as a measure of calcium nodule formation was measured 
using an assay kit according to manufacturer's instructions (ScienceCell). 
Briefly, media were removed from the cell culture dishes and calcium was 
solubilized using 0.1 N HCI. Assay reagent was prepared by mixing equal 
amounts of buffer AMP and ortho-cresolphthalein color reagent. Serial dilutions 
of calcium chloride starting at 20 mM were used as standards. 10 IJI samples or 
standards were incubated with 400 IJI assay reagent for 15 min at room 
74 
temperature. Absorbance was measured at 570 nm and values of a blank were 
subtracted. 
3.6 Multiplex ELISA (Luminex) 
Macrophages were isolated and cultured as described above. At 
confluence, 8 x 1 05 cells were passaged into 24-well plates. After 24 h 
macrophages were stimulated with 1 !JM PGE2 with or without 100 nM RvE 1. 
Cell culture supernatants were collected after 48 h, centrifuged at 4000 x g for 10 
min at 4 oc to remove debris, and stored at -80°C. All reagents were allowed to 
warm to room temperature before use. The assay was performed in duplicate. 
The filter plate was pre-wet by pi petting 200 1-11 of wash buffer into each well of a 
microtiter filter plate. The plate was sealed and shaken for 10 min at room 
temperature. The wash buffer was removed by vacuum. 25 !JI of each standard 
or control were added into the appropriate wells. Assay buffer was used as 
blank. Afterwards, 25 1-11 of the samples were added into the appropriate wells. 
Twenty five !JI of beads containing capture antibodies for TN F-a, M-CSF, 
IL-1 !3, IL-6, IFN-y, and IL-1 0 were added to each well. The plate was sealed, 
covered with the lid, and incubated overnight on a shaker at 4°C. The next day, 
fluid was removed by vacuum. The plate was washed twice with 200 !JI/well of 
wash buffer, and then the wash buffer was removed by vacuum filtration and an 
absorbent pad. 25 !JI of detection antibodies were added into each well. The 
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plate was sealed , covered with a lid and incubated on a shaker for 1 hat room 
temperature. 25 IJI of streptavidin-phycoerythrin were added to each well. The 
plate was sealed, covered with a lid and incubated on a plate shaker for 30 min 
at room temperature. All contents were gently removed by vacuum. The plate 
was washed twice with 200 1JIIwell wash buffer, and the buffer was removed by 
vacuum filtration between each wash. 150 IJI of sheath fluid were added to all 
wells. The fluorescence was measured using a Luminex 1 00 with Bioplex 
. Manager 5.0 (Bio-Rad). The median fluorescent intensity data was plotted using 
a spline curve-fitting method for calculating the cytokine concentrations. 
3.7 Alizarin Red staining of mineralized nodules 
Calvaria osteoblasts were plated in 24-well plates at a density of 2 x 1 04 
cells. After incubation for 21 and 28 days in the presence of media 
supplemented with AA and BGP as described above, cells were fixed with 4% 
formaldehyde in PBS, pH 7.4 for 10 min, and incubated with Alizarin Red dye 




In order to detect ChemR23 receptor mRNA expression, cells were plated 
in 6 well plates at a density of 1 05 cells/well. RNA was collected the next day 
using the phenol-chloroform method (483). eDNA was prepared from 2 IJg RNA. 
Reverse transcription reaction was performed using 1 IJg RNA using 
random hexamers, dNTP, buffer, nuclease-free water, ribonuclease (RNase) 
inhibitor and reverse transcriptase (High-Capacity eDNA Reverse Transcription 
Kit, ABI). The samples were incubated in the GeneAmp PCR 9700 system (ABI): 
25°C for 10 min, 3rC for 2 h, 85°C for 5 min with a total of 20 IJI reaction 
volume. The eDNA products were stored at -20°C and diluted before the real-
time reaction. 
Polymerase chain reaction (PCR) was conducted (Taq Platinum, 
Invitrogen), using primers for ChemR23 (357 bp amplicon): forward primer- 5' -
ACTCGCAAGTAGTTTCCACAGGGT, reverse primer - 5' -
TTCTGAAGTCGTGGCCCATGAAGA. Amplification was performed at the 
following temperatures: 94°C for 2 min, followed by 35 cycles of 94°C for 0.5 min, 
52°C for 0.5 min and one hold of 72°C for 1 min. The products were visualized 
by 1% agarose gel electrophoresis, stained with ethidium bromide and compared 
to the 1 kb Plus DNA Ladder (Invitrogen). 
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3.9 Immunofluorescent staining 
Calvarial osteoblasts were plated on round cover slips in 24-well plates at 
a density of 2 x 104 cells/well. At confluence, media were changed to 
differentiation media (a-MEM media supplemented with 10% FBS, 10,000 IU 
penicillin, 10,000 IJg/ml streptomycin, 50 IJg/ml AA and 10mM BGP) and replaced 
every two days. Antibodies: anti-hChemR23 (R&D Systems #MAB362, clone 
84399), isotype-matched antibody (mouse lgG3 R&D Systems #MAB007, clone 
133316). Time points were 0 and 10 days. At each time point, the cells were 
washed with ice-cold PBS, and then incubated for 10 min with 4% 
paraformaldehyde in PBS pH 7.4 at room temperature. Slides were then washed 
twice with ice-cold PBS and blocked using 5% goat serum in 0.1% Tween 20 in 
PBS (PBS-T) for 1h. The monoclonal primary antibody and the isotype-matched 
control were diluted (1 :100) in 5% goat serum (Sigma) in PBS-T and slides were 
incubated overnight at 4 oc in the dark. The next day, slides were washed 3 
times with PBS-T and incubated in Alexa Fluor 488 goat anti-mouse lgG 
(Invitrogen 1:1 00) in 5% goat serum in PBS-T for 1 h in the dark. The slides were 
washed 3 times with PBS-T and cover slips were mounted using the Prolong 
Gold anti-fade reagent (Invitrogen) , which labels nuclei with 4',6-diamidino-2-
phenylindole (DAPI). Slides were visualized in an Olympus FSX 100 fluorescent 
microscope and data was collected using the FSX-BSW Ver.03.01 software. 
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3.10 VVestern Blot 
Calvaria osteoblasts were isolated, cultured to confluence and passaged 
into 6-well plates at a density of 105 cells/well. Cells were th€m cultured in media 
supplemented with AA and BGP for 10 days. Afterwards, calvaria osteoblasts 
were incubated for 15 min in presence of RvE 1 with or without rapamycin or 
ChemR23 blocker. For rpS6 pathway inhibition, rapamycin was used at 20nM 
(Cell Signaling) and an hChemR23 antibody at a 1:100 dilution from a 500 tJg/ml 
stock (R&D) was used to block the ChemR23 receptor. After the 15 min 
stimulation, cells were washed twice with ice-cold PBS and scraped into 1 ml 
radioimmunoprecipitation assay buffer (RIPA) buffer (150 mM NaCI, 2 mM 
EDTA, 50 mM tris(hydroxymethyl)aminomethane (Tris)-HCI, pH 7.4) 
supplemented with protease and phosphatase inhibitors (Pierce 78440). 
Proteins were prepared by mixing 25 tJg of lysate with 6x sample loading 
buffer (350 mM Tris-HCI, 10% SDS, 36% glycerol, 0.03% (w/v) bromophenol 
blue, 864 mM J3-mercaptoethanol). The lysates were denatured by heating to 
1 oooc for 10 min . The proteins were separated by electrophoresis in 10% or 
12% polyacrylamide gels in running buffer (25 mM Trizma base, 192 mM glycine, 
0.1% sodium dodecyl sulfate (SDS)) at 150 Vfor 1.5 h. Molecular weight 
standards were purchased from Bio-Rad. A polyvinylidene fluoride (PVDF) 
membrane (Bio-Rad) was prepared by 2 min incubation in methanol followed by 
15 min incubation in blotting buffer (25 mM Trizma base, 192 mM glycine, 20% 
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methanol). Proteins were transferred to the prepared PVDF membrane at 333 
rnA for 90 min at 4°C. 
The membrane was incubated in blocking solution (5% (w/v) milk in 20 
mM Tris-HCI, 150 mM NaCI, 0.1% Tween-20 + 5% milk (TBS-T)) for 1 hand then 
incubated with a mixture of primary antibodies overnight at 4 oc 1 :400 in 5% BSA 
in TBS-T on a shaker. The mixture (Cell Signaling) was composed of antibodies 
for the phosphorylated forms of Akt, p42/44 MAPK, p90RSK and rpS6. The 
expected bands were: p90RSK (90 kDa), Akt (60 kDa), p42/44 (42, 44 kDa), and 
rpS6 (32 kDa). For the rpS6 phosphorylation, a serine 235/236 phospho-
antibody was used (Cell Signaling), and the expression was normalized to the 
total rpS6 (Cell Signaling). 
The next day, membranes were washed 3 times with TBS-T for 5 min and 
incubated with 1 :2000 goat anti-rabbit lgG-horse radish peroxidase (HRP) 
secondary antibody (Cell Signaling) in blocking solution for 1 h at room 
temperature. A control membrane was incubated with secondary antibodies to 
rule out non-specific binding. The membrane was then washed 3 times for 5 min 
in TBS-T and the HRP conjugate was detected using a chemiluminescence 
reaction (ECL Western Blotting Substrate, Pierce). An X-ray film (X-Omat Blue 
Film XB, Kodak) was exposed to the membrane and protein bands were 
visualized. Results were normalized to expression of 13-actin (Sigma) . In order to 
assay for additional targets, the membrane was incubated for 15 min in stripping 
buffer (Pierce) and washed 3 times in TBS-T before further processing. 
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3.11 Real time PCR 
MC3T3 cells were plated in 6-well plates at a density of 1 05 cells/well. 
Cells were then cultured in a-MEM media supplemented with AA and BGP as 
described above for 14 days. Media was changed every other day. To measure 
expression of osteoblast-specific genes, total RNA was isolated using the 
phenol-chloroform method (Trizol, Invitrogen). RNA concentration was 
measured by spectrophotometry (Nanodrop, Thermo Scientific) . The RNA 
absorbance ratios of A25o/A2so- 2.0 and A25o/A23o- 1.8-2.2 were considered 
acceptable. 
RNA was also analyzed by 1% agarose gel electrophoresis, and stained 
ethidium bromide, using the NorthernMax Formaldehyde Load Dye (Ambion) with 
an RNA marker (Invitrogen). The RNA was processed to have two intact 18s 
and 28s bands. 
The expression of BSP, RunX2, OCN, and RANKL was measured by real-
time PCR (7000 Sequence Detection System, ABI). The expression was 
normalized to hypoxanthine-guanine phosphoribosyltransferase (HPRT)-1 , which 
was found to be expressed at levels comparable to the target genes and to be 
constant across the experimental groups. Target gene expression is presented 
relative to the control sample, which were cells cultured in media supplemented 
with 10% FBS and 10,000 IU penicillin , 10,000 IJg/ml streptomycin. 
100 ng DNA were used in the reaction. Probes of Taqman chemistry were 
used with a 5' fluorescein amidite (FAM)-Iabeled reporter dye. In this method, 
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the oligonucleotide probe is labeled with a reporter dye on the 5' end and a 
quencher dye on the 3' end. While the probe is intact, the quencher dye reduces 
the fluorescence emitted by the reporter dye by fluorescence resonance energy 
transfer (FRET). The probe anneals to the target sequence. The polymerase 
produces DNA starting at the primer. Its 5' nuclease activity cleaves the reporter 
dye, which can then emit a fluorescent signal. This process results in an 
increase in fluorescence intensity proportional to the amount of amplicon 
produced. 
Assay IDs: bone sialoprotein (Mm00492555_m1), Runx2 
(Mm00501580_m1), RANKL (Mm00441908_m1), HPRT1 (Mm00446968_m1). 
OCN forward: CTGGCTGCGCTCTGTCTCT, reverse: 
GACATGAAGGCTTIGTCAGACTCA, probe: ACCTCACAGATGCCAAG. For 
the real-time reaction, a Taqman Universal PCR Master Mix (Applied 
Biosystems) was used, containing a ROX passive reference dye. Amplification 
was performed at the following temperatures: 50°C for 2 min, 95°C for 10 min , 
followed by 40 cycles of 95°C for 0.15 min and 60°C for 1 min. The fluorescence 
threshold was chosen automatically by the system (Sequence Detection 
Software SDS V1.2.3., ABI). The software recorded the threshold cycle (Ct) 
values, and the endogenous control was subtracted to yield LlCt. These values 
were then normalized to a no-treatment control, resulting in LlLlCt. The final 
results are presented as relative quantification values (RQ=2-Mct). A no-template 
control was used to detect contamination of the PCR reagents. A no-reverse 
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transcription control was used to detect signal due to genomic DNA 
contamination. 
3.12 Protein concentration 
Bradford assay was used to measure protein concentration. A standard 
curve was prepared using serial dilutions of bovine serum albumin (BSA) at 12.5, 
62.5, 125, 250, 375, 500, 750 and 1000 j.Jg/ml. 200 IJI Bradford reagent (Bio-
Rad) were added to 10 j.JI sample and standards and assayed in duplicates. 
Absorbance was measured at 595 nm (Spectramax 340PC384 with SoftMax 
4.3LS, Molecular Devices). Background absorbance of de-ionized water was 
subtracted from all measurements. Sample concentrations were extrapolated 
from the standard curve. 
3.13 Alkaline phosphatase activity 
MC3T3 cells were plated at a concentration of 1 05 cells/well in 6-well 
plates. Cells were cultured in media supplemented with AA and BGP as 
described above for 21 days. Media were changed every other day. 
Cytoplasmic fractions were prepared using an extraction kit (Pierce) and 
incubated with p-nitrophenyl phosphate (pNPP). Reaction was stopped using 
0.5N sodium hydroxide. Optical density (OD) of the products at 405 nm was 
measured by spectrophotometry (Spectramax 340PC 384 with a SoftMax Pro 
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software 4.3LS, Molecular Devices). Enzyme activity was calculated as the OD 
of the reaction product multiplied by the reaction volume, and normalized to the 
reaction time. These values were normalized to protein content as measured 
using the Bradford protein assay, described above. 
3.14 Luciferase NF-kB reporter assay 
MC3T3 cells at 105 cells/well were plated in 6-well plates. The next day, 
medium was replaced with fresh medium 30 min before the transfection . A 
luciferase reporter construct (484) was generously provided by Dr. Gail 
Sonenshein. The NF-kB-Iuciferase reporter construct was diluted in serum-free 
medium, 1 IJg/well. A constitutively active Renilla luciferase reporter construct 
0.1 IJg/well was diluted in serum-free media and used as a reference. Reporter 
solutions were incubated at room temperature for 15 min. 3 IJI/well cationic 
transfection reagent was diluted in serum-free media and incubated at room 
temperature for 15 min. After the incubation, reporters were mixed with the 
transfection reagent and delivered (GenJet, SignaGen Laboratories) . Medium 
was replaced after 5 h. After 48 h, cells were incubated with 100 nM RvE1 , and 
TN F-a was added 30 min later. The culture medium was removed after 4 h of 
incubation , the cells were rinsed with PBS, and lysis buffer (Promega) was added 
to the wells. Cell contents were then scraped from the wells using plastic 
scrapers, transferred to centrifuge tubes and placed on ice. For the 
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luminescence measurement, 20 IJI of lysates were transferred to a 96-well plate. 
A volume of 100 IJI of Luciferase Assay Reagent was added to each well. The 
system read the luminescence and injected a solution that quenched the firefly 
luciferase activity and initiated the Renilla luciferase reaction (Synergy 2 SLD, 
Biotek, VT, with Gen5 Data Analysis Software). Following subtraction of the 
background, luciferase values were normalized to those of the Renil/a luciferase. 
3.15 ELISA 
Calvaria cells were isolated and passaged at confluence into 12-well 
plates at a density of 4 x 104 cells/well. Cells were then cultured in a-MEM media 
supplemented with AA and BGP as described above for 10 days and then 
stimulated with 10 ng/mlll-6 and 10 ng/ml sll-6R (Antigenix) (440) with or 
without 10 nM RvE1, and incubated for 48 h. Supernatants were collected, 
centrifuged at 4000 x g for 10 min at 4°C, and frozen at -80°C until assayed. 
ELISA plates were coated with the OPG (R&D Systems), RANKL 
(Pepretech), or IL-6 (Biolegend) capture antibodies overnight, then washed with 
in PBS-T, blocked using 1% BSA (Sigma) in PBS-T, and incubated with 
standards and samples. The detection antibody diluted in PBS-Twas applied to 
the plates, followed by Avidin-HRP in PBS-T. The colorimetric signal developed 
after incubation with tetramethylbenzidine (TMB)(Sigma) for the OPG and IL-6 
ELISA and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) for 
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RANKL (Sigma), and the reaction was stopped using 2N H2S04 . Absorbance 
was read at 450 nm (Spectramax 340PC 384 with a SoftMax Pro software 4.3LS, 
Molecular Devices), and the background absorbance values were subtracted. 
Sample concentration was calculated based on a standard curve. 
3.16 Statistical methods 
Experiments were performed in duplicates and repeated at least 3 times. 
Results are expressed as means ± standard error of mean (SEM). Comparisons 
between two groups were analyzed using Student's two-tailed unpaired t-test. 
One-way analysis of variance (ANOVA) and Scheffe's post hoc test for multiple 
comparisons were used for comparisons among three or more groups. An a-
level of 0.05 was considered statistically significant. 
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4 Results 
4.1 Aim 1 - Establish the actions of RvE1 in a bone healing model (mouse 
craniotomy) 
Questions: Does RvE1 enhance bone healing in the mouse craniotomy model? 
Does over-expression of the receptor for RvE1 in transgenic mice enhance 
healing? 
Rationale: Prior studies demonstrated that RvE1 acts directly on osteoclasts to 
prevent multinuclear cell formation and to limit bone resorption. However, new 
bone formation requires mineralized extracellular matrix production by 
osteoblasts and regeneration of new bone in the treatment of periodontitis cannot 
be explained by inhibition of osteoclasts only. The hypothesis is that RvE1 
impacts osteoblast function. In order to determine whether RvE1 enhances new 
bone formation, we chose a craniotomy model with injection of exogenous RvE1 
or vehicle. Pilot studies had shown that initial bone healing is observed 14 days 
after a 1 mm craniotomy in mice calvaria. Along with wild type mice, transgenic 
mice over-expressing the RvE1 receptor, ChemR23, were used. The ChemR23 
gene construct was driven by the CD11 b promoter, which is designed to limit 
expression to myeloid cells. It was reasoned that if transgenic mice were 
producing more bone, then the target of RvE1 action would be a myeloid cell. 
Experimental design: Two strains of mice were used in the initial experiment; 
FVB wild-type and hChemR23 over-expressing transgenic mice on the FVB 
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background. Prior work in the Gyurko laboratory produced an RvE1 receptor 
(hChemR23) transgenic mouse model that was used to demonstrate enhanced 
actions of RvE1. The transgenic construct was created by cloning hChemR23 
eDNA downstream to a CD11 b promoter. 
Craniotomy was performed and local injections of RvE1 or vehicle were 
given every other day. Bone healing was assessed by histology after 14 days. 
This time point was selected in order to measure early changes in bone 
formation. The healing rate was quantified as the new bone formed relative to 
the initial defect (Fig. 6). Differences between the RvE1- and the vehicle-injected 
mice and between wild-type mice and ChemR23 transgenic mice were analyzed 
in this experiment. 
Results - In both FVB wild-type mice and in hChemR23 transgenics local 
injections of 100 ng RvE 1 result in significantly improved healing of the calvarial 
defect relative to vehicle-treated controls, p<0.05 (Fig. 7). This effect is stronger 
in the transgenics; RvE1-injected transgenic mice had higher rates of bone 
formation relative to RvE1-injected wild types (p=0.06) , consistent with higher 
expression of the ChemR23 receptors in these mice. In order to assess 
osteoclast numbers, tartrate-resistant acid phosphatase (TRAP) staining was 
performed. No statistically significant differences were found in osteoclast 
numbers: 6.5 .±. 0.64 osteoclasts/mm bone surface in the vehicle group vs. 5.14 .±. 
1.68 osteoclasts I mm in the RvE1 group (p=0.1 ). 
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The increased formation of bone after craniotomy in response to RvE 1 
suggests that there is an increase in the activity or numbers of osteoblasts. The 
fact that the number of osteoclasts is unchanged does not rule out alterations in 
the activity of these cells. 
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Figure 6 - Histological section through calvarial drilling defect. 
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Figure 6- Histological section through calvarial drilling defect. (1 OOx 
magnification). Calvaria from the operated mice were isolated 14 days post-op, 
washed in deionized water, and incubated overnight in 4% formaldehyde in PBS. 
Calvaria were then incubated in 70% ethanol and embedded in paraffin. 6 J.Jm 
coronal sections of the parietal bone were prepared through the center of the 
circular defect and then stained with hematoxylin-eosin (H&E). 
Compact calvarial bone appears in the right and left of the field . At the edge of 
the original defect, newly formed bone is distinguished from the original by its 
spongy appearance. Connective tissue and osteoid are stained pink in the 
middle of the defect. The red line marks the original defect; the green line marks 
the size of the defect at the time of tissue collection. 
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Figure 7- RvE1 injections improve bone formation in wildtype and in hChemR23 
transgenic mice. New bone formation 14 days post-op with local injections of 
100 ng RvE1, given every other day. Histological slides were analyzed and 
results are presented as formation of new bone relative to the original defect. 
For each mouse, average bone formation was calculated based on 
measurements of 3 separate histological sections close to the middle of the 
circular defect. Mean± SEM, * p<0.01, Student's t-test, n=16 in each group. 
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4.2 Aim 2 - Determine the mechanism of action of RvE1 on bone marrow 
macrophages in vitro 
Questions - Is ChemR23 expressed in bone marrow macrophages? Does 
RvE1 alter the production of mineralized matrix by osteoblasts indirectly through 
macrophages? Is macrophage signaling to osteoblasts altered by inflammatory 
stimuli? 
Rationale: From the results of the in vivo experiments, it was evident that RvE1 
enhances bone formation in the craniotomy model. In addition, transgenic 
hChemR23 mice had higher healing rates relative to wild-type controls. 
These facts suggested that RvE1 action on bone formation is mediated in part by 
myeloid cells. Osteal macrophages emerge as an important cellular component 
of bone tissue, and were shown to regulate the function of osteoblasts (343). 
Macrophages are known to actively participate in resolution of inflammation and 
to respond to RvE1 . The hypothesis that the macrophage response to RvE1 will 
alter the function of osteoblasts was tested. 
Experimental design: Bone marrow cells were isolated from 6-8 week-old mice 
and were plated in 10 em dishes (Fig . Sa, 9a) . Macrophages were differentiated 
with 30 ng/ml M-CSF. F4/80 is a surface marker of macrophages and 
monocytes (37) . The expression of macrophage marker F4/80 and the 
ChemR23 receptor were measured by fluorescence-activated cell sorting 
(FAGS). In order to test the response of osteoblasts to signals from 
94 
macrophages, extracellular matrix mineralization was measured in co-culture of 
osteoblasts and macrophages. The production of cytokines by macrophages in 
response to an inflammatory·stimulus was assessed by multiple ELISA. 
Results - In order to validate the cellular phenotype, the expression of F4/80 was 
assayed by FAGS (Fig. 8b). F4/80 was found to be expressed in 93.1% of the 
isolated cells, suggesting that these cells express on their surface a monocyte-
macrophage marker. 
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Figure 8- Bone marrow cells express the F4/80 antigen. 
a). Experimental design: Bone marrow cells were isolated from 6-8-week old 
mice. 4 x 106 cells were plated in tOcm Petri dishes in media supplemented with 
30 ng/ml M-CSF. After 3 days, Sml fresh supplemented medium was added . 
Cells were passaged on day 7 using cell scrapers. 8 x 1 05 cells were plated in 
24-well plates in RPMI supplemented with 30 ng/ml M-CSF. After one day, cells 
were isolated by scraping, and incubated on ice. Cells were centrifuged at 300 x 
g for 5 min at 4°C, the supernatant was discarded, and cells were stained with 
F4/80 FITC-conjugated rat anti-mouse antibody or lgG 2a isotype-matched 
control for 60 minutes in the dark. Antibody was then washed with cold PBS, 
cells were centrifuged, and the pellet was resuspended in FACS buffer and 
analyzed by FACS as described in section 3.4. 
b). 93.1% of the isolated cells express F4/80. Expression of F4/80 (green) is 
shown relative to an isotype-matched control (blue) and no-staining (gray) . Data 
is representative of 3 independent experiments. 
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4.2.1 Is ChemR23 expressed in F4/80+ cells? 
The presence of the ChemR23 receptors in F4/80+ was evaluated. 77% 
of the isolated cells express the RvE1 receptor ChemR23 (Fig. 9b), suggesting 
that these cells are potentially able to respond to RvE 1. 
4.2.2 Does RvE1 alter the production of mineralized matrix by osteoblasts 
indirectly through F4/80+ cells? 
Next it was hypothesized that the calcium content of osteoblast-
macrophage co-cultures stimulated with RvE1 would depend on macrophage 
function. This hypothesis was based on studies that showed that elimination of 
macrophages from a macrophage-osteoblast co-culture causes a decrease in 
formation of mineralized nodules (343). 
Osteoblasts from bone marrow or MC3T3 cells were co-cultured with 
F4/80+ cells using 24-transwell plates with 0.4 j..Jm pore size. Osteoblasts were 
seeded on the bottom of the wells at a density of 2 x 1 04/well and 2 x 105 
macrophages were seeded on the inserts. Media were supplemented with AA, 
BGP and PGE2, and replaced every 2 days for 3 weeks with or without RvE 1 . 
Extracellular matrix mineralization was assessed using a colorimetric calcium 
assay. Cells cultured in supplemented media had increased formation of 
extracellular mineral deposits (13.97 ±. 0.24 mM vs. 3.43 ±. 0.08 mM, mean±. 
SEM, n=4). PGE2 decreased calcium deposition (8.1 ±. 0.46 mM). RvE1 had a 
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similar action in these cultures, decreasing calcium deposition (8.81 .±. 0.36 mM). 
This experiment shows that RvE1 does not alter the reduction in extracellular 
matrix mineralization induced by PGE2 in osteoblasts co-cultured with monocyte-
macrophages. 
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Figure 9 - Bone marrow F4/80+ cells express the ChemR23 receptor. 
a). Experimental design: Bone marrow cells were isolated from 6-8-week old 
mice. 4 x 106 cells were plated in 1 Ocm Petri dishes in media supplemented with 
30 ng/ml M-CSF. After 3 days, 5ml fresh supplemented medium was added. 
Cells were passaged on day 7 using cell scrapers. 8 x 1 05 cells were plated in 
24-well plates in RPMI supplemented with 30 ng/ml M-CSF. After one day, cells 
were isolated by scraping, and incubated on ice. Cells were centrifuged at 300 x 
g for 5 min at 4°C, the supernatant was discarded, and cells were stained with 
ChemR23 PE-conjugated rat anti-mouse antibody or lgG 2a isotype-matched 
control for 60 minutes in the dark. Antibody was then washed with cold PBS, 
cells were centrifuged, and the pellet was resuspended in FAGS buffer and 
analyzed by FAGS as described in section 3.4. 
b). 77% of the cells express ChemR23. Expression of ChemR23 (green) is 
shown relative to an isotype-matched control (blue) and no-staining (gray). Data 
is representative of 3 independent experiments. 
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4.2.3 Is macrophage signaling to osteoblasts altered by inflammatory 
stimuli? 
In order to investigate which inflammatory markers are produced in PGE2-
induced inflammatory conditions, macrophages were cultured in 24-well plates at 
a density of 8 x 105 cells/well. After 24 h, macrophages were stimulated with 1 
IJM PGE2. Supernatants were collected after 48 h and analyzed by multiple 
ELISA for expression of M-CSF, TN F-a, IFN-y, IL-113, IL-1 0, and IL-6 (Fig . 1 Oa). 
The results showed that PGE2 stimulates IL-6 expression. PGE2 with 100 nM 
RvE1 or vehicle stimulated IL-6 expression to similar levels (Fig. 10b). RvE1 
alone did not alter IL-6 levels relative to untreated cells. This experiment 
suggests that F4/80+ cells stimulated with PGE2 respond by specific secretion of 
IL-6 but not other cytokines, and adding RvE1 does not regulate this action . 
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4.3 Aim 3 - Determine the mechanism of action of RvE1 on osteoblasts in 
vitro. 
Questions - Do isolated calvaria cells express an osteoblast phenotype? Is the 
ChemR23 receptor expressed in calvaria osteoblasts? Does RvE1 regulate 
osteoblast differentiation? What functions of osteoblasts are regulated by RvE 1? 
Does RvE1 alter intracellular pathways in osteoblasts? Does RvE1 regulate 
OPG expression in osteoblasts stimulated with IL-6? 
Rationale- Our alternative hypothesis was that RvE1 has a direct action on 
osteoblasts. Following validation of the osteoblast phenotype, calvarial 
osteoblasts were assayed for expression of the ChemR23 receptor. The lysates 
were assayed by immunoblot in order to examine the phosphorylation of multiple 
enzymes known to transduce the message from ChemR23 in leukocytes (1 00, 
173). The action of RvE 1 on osteoblast differentiation was tested in presence of 
inflammatory stimuli. Information on the phenotype of osteoblasts is limited, thus 
in order to assess the action of RvE1 on osteoblast differentiation , experiments 
targeted the expression of bone markers in osteoblasts stimulated with pro-
inflammatory cytokines. To investigate additional functions of osteoblasts, the 
expression of RANKL, the activity of a NF-kB reporter, and the production of 
OPG and RANKL was measured under pro-inflammatory stimulation. 
Experimental design - Cells were isolated from mouse calvaria and 
differentiated into osteoblasts. The phenotype was assessed using Alizarin Red 
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staining to detect calcification and expression of bone markers by real time PCR. 
The expression of the ChemR23 receptor was measured by RT -PCR and 
immunofluorescence. The action of RvE1 on osteoblast differentiation was 
measured by real time PCR and alkaline phosphatase activity assay. The 
intracellular signaling of RvE1 was assessed by Western blotting. In order to test 
the action of RvE1 on osteoblast function, the expression of RANKL was 
measured by real time PCR. NF-kB was assessed using a luciferase reporter 
assay. The action of RvE1 on production of OPG and RANKL by osteoblasts 
exposed to an inflammatory stimulus was measured by ELISA. 
The findings from Aim 2 suggested that the action of RvE 1 on bone 
formation may be directly mediated by osteoblasts. To test the action of RvE1 on 
osteoblasts in vitro, experiments were performed in MC3T3 cells, bone marrow 
and calvaria osteoblasts. The first in vitro experiments were designed to validate 
the osteoblast phenotype and to prove that the cells can potentially respond to 
RvE1. 
The action of RvE1 on osteoblast differentiation was tested by 
measurement of bone markers by real-time PCR. The expression of OPG and 
RANKL was measured by ELISA. RANKL expression was tested by real-time 
PCR and NF-kB was assessed using an NF-kB luciferase reporter assay. In 
order to show that the cells respond to RvE1, we examined the expression of the 
ChemR23 receptor, followed by analysis of hypothesized intracellular signaling 
pathways. 
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4.3.1 Do isolated calvaria cells express an osteoblast phenotype? 
Mouse calvaria osteoblasts were isolated and were passaged prior to 
confluence into 24-well plates at a density of 2 x 1 04 cells/well in tissue culture 
media containing a-MEM, 10% FBS, 10,000 IU penicillin and 10,000 j.Jg/ml 
streptomycin . The next day, media were supplemented with 50 j.Jg/ml AA and . 
10 mM BGP and were replaced every other day for 21 and 28 days. A control 
group was cultured in media without supplements. At the 21- and 28-day time 
points, cells were fixed and an Alizarin Red assay performed. Results show that, 
in contrast to cells cultured in non-supplemented media, calvaria cells cultured in 
media supplemented with AA and BGP produce extracellular mineralized 
nodules, consistent of an osteoblast phenotype (Fig. 11 ). 
To further validate the osteoblast phenotype, we measured the expression 
of bone markers in calvaria osteoblasts. Calvaria cells were plated in 12-well 
plates at a density of 4 x 104 cells/well in media supplemented with AA and BGP. 
Media were changed every other day for 10 days. Control cells were grown in 
non-supplemented media. RNA was isolated after 10 days using phenol-
chloroform extraction, eDNA was prepared by reverse transcription , and the 
expression of BSP and OCN was measured by real-time PCR and analyzed 
using the /j./1Cr method (Fig. 12). The expression of each target gene was 
calculated relative to the HPRT1 endogenous control. Relative to the controls , in 
cells cultured in media supplemented with AA and BGP, the expression of BSP 
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and OCN was significantly higher, consistent of an osteoblast phenotype (n=3, 
p<0.01, T-test). 
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Figure 10- Production of IL-6 is stimulated by PGE2 in bone marrow 
macrophages. 
a). Cells were isolated and differentiated with 30 ng/ml M-CSF for 6 days. 
Afterwards 8 x 105 cells were passaged into 24-well plates. After 24 h PGE2 at a 
final concentration 1 IJM was applied with or without 100 nM RvE1 for 48 h. IL-6 
concentration in the supernatant was measured by ELISA. 
b) . IL-6 concentrations were calculated from a standard curve. Mean.±. SEM, 
*p<0.05, n=3, ANOVA, Scheffe. 
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Figure 11 -Alizarin Red staining of mouse calvaria osteoblasts. 
a). 
Calvaria cell 
isolation AA + BGP, media changed 
every other day 
I Alizarin Red 
b) . 
Control day 21 (Regular media) 
Day 21 (AA-BGP-supplemented media) 
Day 28 (AA-BGP-supplemented media) 
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Figure 11 -Alizarin Red staining of mouse calvaria osteoblasts. 
a). Experimental design - Cells were isolated and 2 x 104 were cultured for 21 
and 28 days in media supplemented with AA and BGP. Media were replaced 
every other day. Cells were then fixed with 4% formaldehyde in PBS pH 7.4 for 
10 min and incubated with Alizarin Red dye for 20 min. 
b). No staining of cells cultured in non-supplemented media. In cultures 
supplemented with AA and BGP, mineralized extracellular matrix is stained in 
red. 
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Figure 12 - Bone sialoprotein (BSP) and osteocalcin (OCN) mRNA are 
increased in calvaria osteoblasts osteoblasts after 10 days of culture in 
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Figure 12 - Bone sialoprotein (BSP) and osteocalcin (OCN) mRNA are increased 
in calvaria osteoblasts after 10 days of culture in media supplemented with AA 
and BGP. 
a). Cells were isolated and 105 were cultured in 6-well plates for 10 days in 
media supplemented with 50 j.Jg/ml AA and 10 mM BGP. Media were changed 
every other day. RNA was isolated after 10 days and reverse-transcribed to 
eDNA. 
b) . Relative quantification (RQ) by real-time PCR, compared to controls (set to 1) 
cultured in non-supplemented media. Mean 2:. SEM, n=3, p<0.01, t-test. 
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4.3.2 Is the ChemR23 receptor expressed in calvaria osteoblasts? 
The ChemR23 receptor was shown to mediate RvE1 action in leukocytes. 
Therefore we set to demonstrate the expression of this receptor in MC3T3 cells 
and calvaria osteoblasts. As described above, 1 05 mouse MC3T3 cells and 
mouse calvaria osteoblasts were cultured in 6-well plates in media supplemented 
with 50 1-Jg/ml AA and 10 mM BGP. RNA was isolated on days 1 and 10 of 
culture. ChemR23 is expressed in calvaria and MC3T3 cells cultured for 1 or 10 
days in supplemented media (Fig. 13). 
The expression of ChemR23 was also evaluated at the protein level by 
immunofluorescent staining. Calvarial osteoblasts were isolated and prior to 
confluence were passaged onto glass cover slips in 24-well plates at a density of 
2 x 104 cells/well. Control cells were grown in non-supplemented media. For 
osteoblast differentiation, cells were grown in media supplemented with AA and 
BGP. After 1 or 10 days in culture , cells were fixed and incubated with a 
ChemR23 antibody and visualized using a fluorescent dye-conjugated secondary 
antibody. ChemR23 was expressed in calvarial osteoblasts on day 1 (Fig. 14) 
and after 10 days of culture in supplemented media (Fig. 15). Expression was 
compared to unstained cells and cells incubated with an lgG3 isotype-matched 
control. The expression of ChemR23 mRNA and presence of ChemR23 on the 
surface of osteoblasts means that the cells can potentially respond to RvE1 
stimulus. 
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Figure 13- Expression of ChemR23 mRNA (357 bp). 
a). Experimental design - Cells were isolated and 105 were cultured in media 
supplemented with AA and BGP. Media were changed every other day. After 1 
and 10 days RNA was isolated, reverse-transcribed to eDNA, and RT-PCR was 
performed with primers specific for ChemR23 as described in section 3.8. 
b). Mouse MC3T3 cells c). Mouse calvaria osteoblasts. L- 1kb Plus DNA ladder 
(Invitrogen), lane 1 -day 1, lane 2- Day 10 cells cultured in media 
supplemented with 50 IJg/ml AA and 10 mM BGP. Bands were visualized by 1% 
agarose gel electrophoresis stained with ethidium bromide. 
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Figure 14- ChemR23 immunostaining in calvaria osteoblasts on day 1 of culture. 
A). Experimental design - Cells were isolated and 2 x 104 were cultured in 24-well 
plates on glass coverslips. The next day cells were washed with ice-cold PBS, 
and then incubated for 10 min with 4% paraformaldehyde in PBS pH 7.4 at room 
temperature. Slides were then washed twice with ice-cold PBS and blocked 
using 5% goat serum in 0.1% Tween 20 in PBS (PBS-T) for 1 h. The monoclonal 
primary antibody and the isotype-matched control were diluted (1 :100) in 5% 
goat serum (Sigma) in PBS-T and slides were incubated overnight at 4oC in the 
dark. The next day, slides were washed 3 times with PBS-T and incubated in 
Alexa Fluor 488 goat anti-mouse lgG (Invitrogen 1:1 00) in 5% goat serum in 
PBS-T for 1 h in the dark. The slides were washed 3 times with PBS-T and cover 
slips were mounted using the Prolong Gold anti-fade reagent (Invitrogen), which 
labels nuclei with 4' ,6-diamidino-2-phenylindole (DAPI) . Slides were visualized in 
an Olympus FSX 100 fluorescent microscope and data was collected using the 
FSX-BSW Ver.03.01 software. 
B). a). Control- no staining b) . lgG3 isotype-matched control c). ChemR23 
staining. 1 ). Phase contrast 2). Alexa 488-conjugated secondary antibody 3) . 
DAPI 4) . Overlay of the ChemR23- and DAPI-stained images. Magnification 
400x. 
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Figure 15 - ChemR23 immunostaining in calvaria osteoblasts after 10 days of 
culture in media supplemented with 50 j.Jg/ml AA and 10 mM BGP. 
A) . Media were changed every other day. Cells were isolated and 2 x 104 cells 
were cultured in 24-well plates on glass coverslips. The next day cells were 
washed with ice-cold PBS, and then incubated for 10 min with 4% 
paraformaldehyde in PBS pH 7.4 at room temperature. Slides were then washed 
twice with ice-cold PBS and blocked using 5% goat serum in 0.1% Tween 20 in 
PBS (PBS-T) for 1 h. The monoclonal primary antibody and the isotype-matched 
control were diluted (1 :100) in 5% goat serum (Sigma) in PBS-T and slides were 
incubated overnight at 4 oc in the dark. The next day, slides were washed 3 
times with PBS-T and incubated in Alexa Fluor 488 goat anti-mouse lgG 
(Invitrogen 1:1 00) in 5% goat serum in PBS-T for 1 h in the dark. The slides 
were washed 3 times with PBS-T and cover slips were mounted using the 
Prolong Gold anti-fade reagent (Invitrogen}, which labels nuclei with 4',6-
diamidino-2-phenylindole (DAPI). Slides were visualized in an Olympus FSX 100 
fluorescent microscope and data was collected using the FSX-BSW Ver.03.01 
software. 
B). a). Control- no staining b). lgG3 isotype-matched control c) .ChemR23 
staining. 1). Phase contrast 2) . Alexa 488-conjugated secondary antibody 3). 
DAPI 4). Overlay of the ChemR23- and DAPI-stained images. Magnification 
400x. 
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4.3.3 Does RvE1 regulate osteoblast differentiation? 
The next experiments were designed to test whether RvE1 regulates 
osteoblast differentiation under pro-inflammatory stimulation. MC3T3 cells were 
plated at a density of 105 cells/well in 6-well plates, and all experimental groups 
were stimulated with AA and BGP for 14 days to stimulate osteoblast 
differentiation (Fig. 16). PGE2, a pro-inflammatory mediator, is produced in the 
early stages of inflammation and participates in the recruitment of leukocytes. 
PGE2 was used to inhibit osteoblast differentiation, by supplementing media 
every other day to a final concentration of 1 !JM. RvE1 was also added to the 
experimental groups at a final concentration of 100 nM. 
The expression of the bone markers BSP and OCN was assayed by real 
time PCR (Fig. 17, 18). Supplementation of the media with AA and BGP induced 
an increase in the expression of BSP relative to cells cultured in un-
supplemented media. PGE2 induced a decrease in BSP but not OCN expression . 
RvE1 did not block the PGE2-induced decrease in BSP expression. Osteoblast 
differentiation did not induce an increase in OCN in these experiments. 
Next we tested the action of RvE1 on TN F-a stimulation of osteoblasts. 
TN F-a is a cytokine known to inhibit bone differentiation. In ChemR23-
transfected HEK 293 cells, RvE1 was shown to inhibit TN F-a signaling (1 00). 
The design of these experiments is described below (Fig. 19). Media 
supplemented with AA and BGP were changed every other day for 14 days. 
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Media were supplemented with TNF-a at a final concentration of 1 ng/ml with or 
without 100 nM RvE1 every other day. 
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Figure 16 - Experimental design. 
Control 
AA + BGP 
AA + BGP + PGE2 11Jg/ml + Vehicle (0 .04% ethanol) 
AA + BGP + PGE2 11Jg/ml 
PGE2/RvE1 





every 2 days 
AA + BGP + PGE2 11Jg/ml + RvE1 1 OOnM 
AA + BGP + RvE1 100nM 
Bone marker mRNA 
expression 
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Figure 16- Experimental design. In the osteoblast differentiation groups, media 
were supplemented with AA and BGP. MC3T3 cells were plated at a density of 
105 cells I well in 6-well plates. Media were supplemented with 50 J..lg/ml AA and 
1 0 mM BGP and changed every other day. Experimental groups were stimulated 
with PGE2 at a final concentration of 1 1-1M with or without 100 nM RvE1 every 
other day. RNA was isolated after 14 days, eDNA was prepared by reverse 
transcription and gene expression was measured by real-time PCR. 
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Figure 17 - Bone sialoprotein (BSP) expression in MC3T3 cells upon PGE2 
stimulation by real-time PCR. MC3T3 cells were cultured in media supplemented 
with AA and BGP and changed every other day. PGE2 at 1 ~M was applied 
every other day with or without 100 nM RvE1. RNA was isolated after 14 days, 
eDNA was prepared and BSP expression was measured by real time PCR. 
There was an increase in BSP in cells cultured in supplemented media, and 
PGE2 blocked this increase. Values are expressed as relative quantification 
(RQ) relative to cells cultured with non-supplemented media (set to 1 ). Mean + 
SEM, n=4, *p<0.05, ANOVA, Scheffe. 
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Figure 18 - Osteocalcin (OCN) expression in MC3T3 cells upon PGE2 
stimulation. MC3T3 cells were plated at a density of 105 cells/well in 6-well 
plates in media supplemented with 50 !Jg/ml AA and 10 mM BGP, and media 
were changed every other day. PGE2 at 1 !JM was applied every other day with 
or without 1 00 nM RvE 1. RNA was isolated after 14 days, eDNA was prepared 
and OCN expression was measured by real time PCR. 
AA and BGP increased OCN expression in MC3T3 cells, and stimulation with 
PGE2 blocked this increase. Relative quantification (RQ}, normalized to 
expression in cells cultured with non-supplemented media (set to 1 ). Mean + 
SEM, n=3. 
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Figure 19 - Experimental design 
Control 
AA + BGP 
TNF/RvE1 





every 2 days 
AA + BGP + TNF 1ng/ml +Vehicle (0.04% ethanol) 
AA + BGP + TNF 1ng/ml 
AA + BGP + TNF 1ng/ml + RvE1 100nM 
AA + BGP + RvE1 100nM 
Bone marker mRNA 
expression 
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Figure 19- Experimental design. In the osteoblast differentiation groups, media 
were supplemented with AA and BGP. In the co-stimulation groups, RvE1 was 
added and after 30 min the cells were stimulated with TNF-a. MC3T3 cells were 
plated at a density of 105 cells I well in 6-well plates. Media were supplemented 
with 50 IJg/ml AA and 10 mM BGP and changed every other day. Experimental 
groups were stimulated with TNF-a at a final concentration of 1 ng/ml with or 
without 100 nM RvE1 every other day. RNA was isolated after 14 days, eDNA 
was prepared by reverse transcription, and gene expression was measured by 
real-time PCR. 
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Previous studies have shown that osteogenic differentiation of MC3T3 
cells causes an increase in the expression of BSP 6-8 days after the beginning of 
the stimulation (246) . We observed a robust increase in BSP after 14 days of 
culture in supplemented media (Fig. 20). TNF-a at 1 ng/ml inhibited this 
increase. RvE1 at 1 OOnM did not alter the inhibition induced by TN F-a. RvE1 
alone did not alter BSP expression. 
RunX2 is a transcription factor found to be important in several steps of 
osteoblast differentiation. Among other functions, Runx2 is associated with the 
production of collagen, the basic component of bone extracellular matrix (188) . 
Upon induction of differentiation, Runx2 expression increased in cells grown in 
supplemented media, p<0.05. TNF-a significantly inhibited the expression of 
RunX2 (p<0.05) and RvE1 did not alter this inhibition (Fig. 21). RvE1 alone did 
not alter RunX2 expression. Thus RvE1 does not alter the expression of BSP, 
OCN or RunX2 in osteoblasts in vitro under pro-inflammatory conditions induced 
by PGE2 or TN F-a. 
ALP is an important marker of osteoblast function and differentiation. ALP 
activity was shown to increase in the first 24 days of mouse MC3T3 osteoblast 
differentiation (203) . In our experiments, the impact of RvE1 on ALP activity was 
measured in the cytoplasmic fractions of MC3T3 cells cultured for 21 days in 
media supplemented with AA and BGP. Media were changed every other day. 
After 21 days, the cells were lysed in the presence of protease inhibitors and the 
cytoplasmic fractions were obtained by centrifugation. The ALP assay did not 
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detect differences between the experimental groups (Fig. 22) . These 
experiments suggest that RvE1 does not alter osteoblast differentiation as it 
measured by expression of bone marker mRNA. 
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Figure 20 - BSP mRNA expression in MC3T3 cells upon TNF-a stimulation. 
In the osteoblast differentiation groups, media were supplemented with AA and 
BGP. In the co-stimulation groups, RvE1 was added and after 30 min the cells 
were stimulated with TN F-a. MC3T3 cells were plated at a density of 1 05 cells I 
well in 6-well plates. Media were supplemented with 50 IJg/ml AA and 10 mM 
BGP and changed every other day. Experimental groups were stimulated with 
TNF-a at a final concentration of 1 ng/ml with or without 100 nM RvE1 every 
other day. RNA was isolated after 14 days, eDNA was prepared by reverse 
transcription, and gene expression was measured by real-time PCR. 
AA and BGP increase bone BSP expression in MC3T3 cells. TNF-a blocks this 
increase. Relative quantification (RQ), normalized to expression in control cells 
cultured with non-supplemented media (set to 1). Mean+ SEM, * p<0.05 relative 
to the AA+BGP-supplemented cells, ANOVA, Scheffe. 
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Figure 21 - RunX2 mRNA expression in bone marrow cells upon TNF-a 
stimulation. 
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Figure 21 - RunX2 mRNA expression in bone marrow cells upon TNF-a 
stimulation. In the osteoblast differentiation groups, media were supplemented 
with AA and BGP. In the co-stimulation groups, 'RvE1 was added and after 30 
min the cells were stimulated with TN F-a. MC3T3 cells were plated at a density 
of 105 cells I well in 6-well plates. Media were supplemented with 50 IJg/ml AA 
and 10 mM BGP and changed every other day. Experimental groups were 
stimulated with TN F-a at a final concentration of 1 ng/ml with or without 100 nM 
RvE1 every other day. RNA was isolated after 14 days, eDNA was prepared by 
reverse transcription, and gene expression was measured by real-time PCR. 
Relative quantification (RQ), expression compared to control cells cultured in 
non-supplemented media (set to 1 ). AA and BGP induced an increase in the 
expression of RunX2 relative to control cells cultured in non-supplemented 
media, *p<0.05 relative to AA + BGP-supplemented cells. Mean± SEM, n=3, 
ANOVA, Scheffe. 
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Figure 22 -Alkaline phosphatase (ALP) activity in MC3T3 cells. 
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Figure 22- Alkaline phosphatase (ALP) activity in MC3T3 cells cultured for 21 
days in media supplemented with AA and BGP. In the osteoblast differentiation 
groups, media were' supplemented with AA and BGP. In the co-stimulation 
groups, RvE1 was added and after 30 min the cells were stimulated with TNF-a. 
MC3T3 cells were plated at a density of 105 cells I well in 6-well plates. Media 
were supplemented with 50 j.Jg/ml AA and 10 mM BGP and changed every other 
day. Experimental groups were stimulated with TNF-a at a final concentration of 
1 ng/ml with or without 100 nM RvE1 every other day. After 21 days, cells were 
lysed and cytoplasmic fractions were prepared using an extraction kit and 
incubated with p-nitrophenyl phosphate (pNPP). Reaction was stopped using 
0.5N sodium hydroxide. Optical density (00) of the products at 405 nm was 
measured by spectrophotometry. Enzyme activity was calculated as the 00 of 
the reaction product multiplied by the reaction volume, and normalized to the 
reaction time. These values were normalized to protein content as measured 
using the Bradford protein assay. Mean.± SEM, n=3, ANOVA. 
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4.3.4 Does RvE1 regulate RANKL mRNA and NF-kB activation? 
In addition to differentiation parameters, we investigated the action of 
RvE1 on expression of RANKL. RANKL is part of the TNF-family of cytokines 
(284, 285) and is a crucial determinant of bone resorption in vivo, due to its 
stimulation of osteoclast differentiation (199). Arachidonic acid and PGE2 
stimulate RANKL expression in MC3T3 cells, while EPA or DHA reduce this 
action in cells treated with PGE2. PGE2 also inhibits OPG expression, regardless 
of co-treatment with EPA or DHA (485). 
In our experiments, the expression of RANKL mRNA in MC3T3 cells was 
minimal. In bone marrow cells, however, RANKL mRNA was detectable. 
Nevertheless, its levels were not significantly altered by TN F-a (Fig. 23). This 
experiment suggests that RvE1 does not alter the expression of RANKL mRNA, 
which is an important factor for osteoclast differentiation and therefore bone 
resorption . 
We also examined the action of RvE1 on NF-kB activation following TNF-a 
stimulation. NF-kB is an important intracellular mediator of immune response 
and inflammation (486-490). In addition to its role in osteoclastogenesis (491 ), 
new evidence shows that NF-kB also has direct action on osteoblast 
differentiation. NF-kB was found to be responsible for impaired bone formation in 
osteoporosis (492). Specific inhibition of NF-kB was found to increase bone 
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formation and reduce osteopenia in ovariectomized mice. RvE1 inhibited NF-kB 
luciferase reporter activity in ChemR23-transfected cells (1 00). 
For this experiment, MC3T3 cells were transiently transfected with a firefly 
luciferase NF-kB reporter construct as well as a constitutively active Renilla 
luciferase reporter construct. Cells were then stimulated with TNF-a and RvE1. 
After 4h, cells were lysed and a Duai-Luciferase Reporter Assay System was 
used to detect differential activity of the NF-kB-Iucifererase reporter. TN F-a 
caused an increase in luciferase activity relative to the controls. However, 
incubation with RvE1 did not inhibit this action of TN F-a in MC3T3 cells. RvE1 
alone did not induce changes in NF-kB activity (Fig. 24). These results suggest 
that NF-kB, which mediates osteoblast functions, is not regulated by RvE1. 
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Figure 23- Expression of RANKL mRNA in bone marrow osteoblasts on day 7 
and 14 of differentiation. 
a). Experimental design - Cells were isolated from 6-8 weeks old FVB mice bone 
marrow and plated in 6-well plates at a density of 107 cells/well in a-MEM 
supplemented with 10% FBS, 10,000 IU penicillin, and 10,000 ~g/ml 
streptomycin. After 6 days in culture, media were supplemented with AA, BGP, 
and 1 o-a M dexamethasone. Media were changed every other day. Cells were 
stimulated with 1 ng/ml TN F-a with or without 100 nM RvE1 every other day. 
RNA was isolated after 7 and 14 days, eDNA was prepared, and gene 
expression was analyzed by real-time PCR. 
b). Relative quantification (RQ), normalized to control cells cultured in non-
supplemented media (set to 1). Mean.±. SEM, n=3. 
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Figure 24- NF-kB-Luciferase reporter activity in MC3T3 cells upon TNF-a/RvE1 
stimulation. a). Experimental design - MC3T3 cells at 105 cells/well were plated 
in 6-well plates. The next day, medium was replaced with fresh medium 30 min 
before the transfection. The NF-kB-Iuciferase reporter construct was diluted in 
serum-free medium, 1 IJg/well. A constitutively active Renilla luciferase reporter 
construct 0.1 IJg/well was diluted in serum-free media and used as a reference. 
Reporter solutions were incubated at room temperature for 15 min. 3 IJI/well 
cationic transfection reagent was diluted in serum-free media and incubated at 
room temperature for 15 min. After the incubation, reporters were mixed with the 
transfection reagent and delivered. Medium was replaced after 5 h. After 48 h, 
cells were incubated with 100 nM RvE1, and TNF-a was added 30 min later. The 
culture medium was removed after 4 h of incubation, the cells were rinsed with 
PBS, and lysis buffer was added to the wells. Cell contents were then scraped 
from the wells using plastic scrapers, transferred to centrifuge tubes and placed 
on ice. For the luminescence measurement, 20 IJI of lysates were transferred to 
a 96-well plate. A volume of 100 IJI of Luciferase Assay Reagent was added to 
each well. The system read the luminescence and injected a solution that 
quenched the firefly luciferase activity and initiated the Renilla luciferase reaction . 
b). Following subtraction of the background , luminescence values (RLU = relative 
luminescence units) were normalized to those of the Renilla luciferase. TN F-a 
increased NF-kB luciferase reporter activity. *p<0.05, Mean± SEM, n=3, 
ANOVA, Scheffe. 
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4.3.5 Does RvE1 alter intracellular pathways in osteoblasts? 
As shown above, RvE1 increases bone formation in vivo. The RvE1 
receptor ChemR23 is expressed in osteoblasts, thus It was of interest to 
investigate the mechanism of signal transduction of RvE1 in these cells. 
Towards that goal, calvaria osteoblasts were isolated , cultured to confluence and 
passaged into 6-well plates at a density of 1 05 cells/well. Osteoblasts were 
cultured for 10 days in media supplemented with AA and BGP. The cells were 
then incubated in the presence of RvE1 for 15 min and lysed with protease and . 
phosphatase inhibitors. The expression of phosphorylated forms of enzymes in 
the MAPK and Akt pathways was assessed by Western blot. 
An initial screening experiment targeted the phosphorylated forms of p90, 
Akt, p42/44 and rpS6. These targets were chosen, because the Akt and MAPK 
pathways were shown to mediate the action of RvE1 in other cells types (1 00). 
Akt is a protein kinase that mediates signals of survival and apoptosis (493-495). 
In addition, Akt phosphorylates mTOR, which mediates cell growth (496). p90 is 
a ribosomal protein that functions downstream of MAPK and PI3K. 
· rpS6 stimulates translation of ribosomal proteins, elongation factors 
necessary for translation, and proteins involved in cell cycle progression (497, 
498) . In MC3T3 cells , rpS6 is expressed during the proliferation period and 
decreases after day 10 of differentiation (236). 
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The MAPK pathway has been previously shown to mediate osteoblast 
differentiation through a2131 integrins after ECM binding (243, 246, 499). Akt was 
also found to promote osteoblast differentiation and survival (500) . 
Therefore the purpose of this assay was to gather information on both the 
PI3K and MAPK pathways (Fig . 25). Quantification of the bands from figure 26 
and normalization with 13-actin showed an increase in the phosphorylation of rpS6 
in response to RvE1 (Fig. 27). 
Following this initial screening, our experiments focused on the 
phosphorylation of rpS6. We measured phosphorylation of rpS6 using an 
antibody specific to the serine 235, 236 phosphorylation sites. These sites are 
located within a small, carboxy-terminal region of the rpS6 protein (501, 502). 
The increased phosphorylation of rpS6 in response to RvE1 confirmed the 
previous experiment (Fig. 28). 
Incubation with 20nM rapamycin caused a decrease in the 
phosphorylation of rpS6 in presence of RvE1. Rapamycin is an inhibitor of mTor, 
which is known to function upstream of rpS6. This result indicates that RvE1 
signals through mTOR to increase rpS6 phosphorylation. 
In order to prove that ChemR23 mediates the function of RvE1, the action 
of RvE1 on rpS6 phosphorylation was also measured in the presence of a 
ChemR23 blocking antibody. Incubation of calvarial osteoblasts with RvE1 in the 
presence of the ChemR23 blocking antibody caused a decrease in the 
phosphorylation of rpS6, showing specificity of RvE1 function through the 
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ChemR23 receptor. These experiments show that RvE1 signals in osteoblasts 
through ChemR23 and the Akt pathway. 
4.3.6 Does RvE1 regulate OPG expression in osteoblasts stimulated with 
IL-6? 
The fact that macrophages express IL-6 in inflammatory conditions raised 
the hypothesis that RvE1 would act on osteoblasts that are stimulated with IL-6. 
IL-6 is a cytokine known to be involved in the pathogenesis of several bone 
diseases (39). The actions of IL-6 on osteoclastogenesis were shown to be 
mediated through the RANKL-OPG system (441). OPG, a secreted decoy 
receptor for RANKL that belongs to the TNF receptor superfamily, is known to 
inhibit osteoclast differentiation (31 0). 
As mentioned, the ratio between OPG and RANKL determines the 
balance between bone formation and resorption. Therefore, the expression of 
OPG and sRANKL upon IL-6 sti'mulation was measured in supernatants of bone 
marrow and calvaria osteoblasts. 
Bone marrow osteoblasts were plated in 12-well plates at a density of 4.8 
x 106 cells/well and differentiated for 10 days as described above. Osteoblasts 
were stimulated with IL-6 at a concentration of 10 ng/ml each, with or without 10 
nM RvE 1. Supernatants were collected after 48 h and analyzed by ELISA OPG 
expression was significantly inhibited by IL-6 or IL-6 with vehicle, while RvE1 was 
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able to block this inhibition and bring the OPG values to the levels of the controls 
(Fig. 29). The same supernatants were also analyzed for expression of sRANKL 
by ELISA (Fig. 30). 
In order to validate these observations in bone marrow osteoblasts, the 
experiments were repeated with calvaria osteoblasts (Fig . 31, 32). The results in 
calvaria osteoblasts confirmed the previous observations. As no differences in 
RANKL were found with RvE1 treatment, the net result from these two 
experiments was an increase in the OPG:RANKL ratio upon RvE1 stimulation, 
suggesting that RvE1 inhibits the osteoclast-recruitment action initiated by IL-6. 
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Figure 25- The Akt and MAPK pathways reported in osteoblasts (243, 246, 
499, 500). 
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Figure 26- lmmunoblot of calvaria osteoblasts stimulated with RvE1. 
a). Experimental design- Calvaria osteoblasts were isolated, cultured to 
confluence and passaged into 6-well plates at a density of 1 05 cells/well. Cells 
were then cultured in media supplemented with AA and BGP for 10 days. Media 
were changed every other day. Afterwards cells were incubated with 1 0 nM 
RvE1 or vehicle in duplicates. After the 15 min stimulation, cells were washed 
twice with ice-cold PBS and scraped into 1 ml RIP A buffer with protease and 
phosphatase inhibitors. 
b) . 25 IJg lysates were assayed by immunobloting. The targets were p90, Akt, 
p42/44 and rpS6. Image is representative of n=3, expression was normalized to 
13-actin. 
c). Screening of p42/44 and MAPK pathways upon RvE1 stimulation in calvaria 
osteoblasts. Quantification of optical densities of blots shown in panel a). relative 
to a no-treatment control (set to 1). 13-actin was used as an endogenous control. 
Mean.±. SEM, *p<0.05, n=6, ANOVA, Scheffe. 
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Figure 27- RvE1 increases phosphorylation of rpS6 in calvaria osteoblasts on 
day 10 of differentiation. 
a) . Experimental design- Calvaria osteoblasts were isolated, cultured to 
confluence and passaged into 6-well plates at a density of 105 cells/well. Cells 
were then cultured in media supplemented with AA and BGP for 10 days. Media 
were changed every other day. Afterwards cells were incubated with 1 0 nM 
RvE1 or vehicle in duplicates. For rpS6 pathway inhibition, rapamycin was used 
at 20 nM and an hChemR23 antibody at a 1:100 dilution from a 500 IJg/ml stock 
was used to block the ChemR23 receptor. After the 15 min stimulation, cells 
were washed twice with ice-cold PBS and scraped into 1 ml RIP A buffer with 
protease and phosphatase inhibitors. 25 IJg lysates were assayed by 
immunobloting. 
b). Quantification of optical densities of phospho/total bands normalized to 13-
actin. Mean± SEM, n=3, *p<0.05, ANOVA, Scheffe. 
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Figure 28 - RvE1 rescues OPG secretion in bone marrow osteoblasts 
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Figure 28- RvE1 rescues OPG secretion in bone marrow osteoblasts stimulated 
with IL-6. 
a) . Experimental design - Cells were isolated and plated at a density of 4.8 x 1 06 
cells/well in 12-well plates. Media were supplemented with AA and BGP and 
replaced every other day. After 10 days, cells were stimulated with 10 ng/mlll-6 
and 10 nM RvE1 . Supernatant was collected after 48 hand analyzed by ELISA. 
b) . OPG concentrations were calculated using a standard curve. Mean.± SEM, 
*p<0.04, n=3, ANOVA, Scheffe. 
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Figure 29 - sRANKL secretion in bone marrow osteoblasts is not altered by 
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Figure 29- sRANKL secretion in bone marrow osteoblasts is not altered by IL-6 
and RvE1 . 
a) . Experimental design -Cells were isolated and plated at a density of 4 .8 x 106 
cells/well in 12-well plates. Media were supplemented with AA and BGP and 
replaced every other day. After 10 days, cells were stimulated with 10 ng/ml IL-
6, 10 ng/ml sll-6R and 10 nM RvE1. Supernatants were collected after 48 hand 
analyzed by ELISA. 
b). sRANKL concentrations were calculated using a standard curve. Mean.±. 
SEM, n=3. 
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Figure 30 - RvE1 rescues OPG secretion in calvaria osteoblasts stimulated 
with IL-6. 
a). 
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Figure 30- RvE1 rescues OPG secretion in calvaria osteoblasts stimulated with 
IL-6. 
a). Experimental design - Cells were isolated and plated at a density of 2 x 104 
cells/well in 24-well plates. Media were supplemented with AA and BGP and 
replaced every other day. After 10 days, cells were stimulated with 10 ng/mlll-
6, 10 ng/ml sll-6R, and 10 nM RvE1. Supernatant was collected after 48 hand 
analyzed by ELISA. 
b). OPG concentrations were calculated using a standard curve. Mean.±. SEM, 
*p<0.04 relative to AA + BGP, n=3, ANOVA, Scheffe. 
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Figure 31 - sRANKL secretion in calvaria osteoblasts is not altered by IL-6 and 
RvE1 . 
a) . Experimental design - Cells were isolated and plated at a density of 4.8 x 1 06 
cells/well in 12-well plates. Media were supplemented with AA and BGP and 
replaced every other day. After 10 days, cells were stimulated with 10 ng/mlll-6 
and 10 ng/ml sll-6R and 10 nM RvE1. Supernatant was collected after 48 hand 
analyzed by ELISA. 
b) . sRANKL concentrations were calculated using a standard curve. Mean+ 
SEM, n=3, *p<0.02, ANOVA, Scheffe. 
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5 Discussion 
Our primary interest in this project was to characterize the function of 
RvE1 in bone regeneration . The hypothesis was that RvE1 induces bone 
formation by direct action on osteoblasts or indirectly through macrophages. In 
this study, it was demonstrated that local injections of RvE1 enhanced bone 
formation in an in vivo craniotomy model in mice. A stronger increase in bone 
formation was found in a transgenic model of over-expression of the RvE1 
receptor, ChemR23. This suggests that the action of RvE1 is mediated by the 
ChemR23 receptor through macrophages. Further experiments, however, 
revealed that RvE1 stimulation of osteoblasts through macrophages was not 
demonstrable. RvE1, however, may act directly on osteoblasts. Osteoblasts 
express ChemR23 mRNA and protein. RvE1 signaling is blocked by specific 
antibody to ChemR23 and by rapamycin, demonstrating the specificity of the 
receptor interaction and the signaling pathway. A potential mechanism for direct 
action of RvE1 on osteoblasts is suggested by in vitro experiments. In these 
experiments, RvE1 rescued downregulation of OPG caused by IL-6, promoting a 
RANKL:OPG ratio favorable to suppression of bone resorption, thus supporting 
net bone formation in the bone remodeling cycle. The production of RANKL was 
not altered by RvE1 in these experiments, leading to the conclusion that RvE1 
induces a net decrease in RANKUOPG in IL-6-stimulated osteoblasts. 
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The interaction between bone cells and the immune system is the focus of 
osteoimmunology. Osteoblasts and osteal macrophages are important factors in 
this interaction. Osteoblasts are known to be stimulated by pro-inflammatory 
mediators and to perform innate immunological functions such as phagocytosis, 
detection of bacterial products, and antigen presentation. Inflammation and bone 
healing are inseparable processes; however, little is known about the interaction 
between the immune response and bone. Clearly, certain cytokines are known 
to have direct actions on bone (IL-1, IL-6), but the cellular mechanisms that 
regulate these actions are poorly understood. The data presented here suggest 
a role for osteoblasts as responder cells in innate immunity. 
Dietary supplementation with w-3 PUFA has been shown to promote bone 
health by decreasing bone turnover and increasing bone mineral density (BMD) 
(1 08, 503-506). In rat bone marrow, EPA supplementation was found to increase 
18-HEPE, the precursor for theE-series resolvins (507). The action of w-3 
PUFA on bone function is associated with several mechanisms: increase of 
calcium absorption in the intestine, reduction of urinary calcium excretion , and 
enhancement of collagen synthesis and bone mineralization. The action of w-3 
PUFA at the cellular level is not yet fully understood. In the bone marrow, w-3 
PUFA may act on the differentiation of mesenchymal stem cells (MSC) into 
adipocytes or osteoblasts (508), a process altered by aging in favor of adipocyte 
differentiation (508-51 0). 
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Resolvins were shown to promote resolution in multiple systems 
throughout the body by specific binding to GPCRs (Table 1 ). The use of 
resolution agonists in inflammation has the potential to enhance healing and to 
reduce side effects of anti-inflammatory drugs currently in use. 
It was therefore of interest to study the precise action of these derivatives 
in bone regeneration, where acute inflammation is the initiating phase. In a 
rabbit model of periodontal disease, it has been shown that local application of 
RvE1 induces bone regeneration (1); in vitro studies showed that RvE1 inhibits 
osteoclast function (2). The next question to be addressed was the action of 
RvE 1 on osteoblasts. 
The action of RvE 1 upon bone regeneration was tested in vivo in a 
surgical model using mouse calvaria. The time point of 14 days was chosen 
based on preliminary experiments. At this stage of healing, the acute 
inflammation had subsided. The cells prevalent in the healing zone were 
osteoblasts. When compared to the vehicle control, calvarial bone healing was 
increased by local injections of RvE1 , healing being more pronounced in the 
hChemR23 transgenic mice (Fig . 7). The observation that osteoclast numbers 
were not altered by the RvE 1 injections in situ suggests that the increased rate of 
healing observed was due to increased bone formation rather than decreased 
bone resorption. Previous results from this laboratory show that RvE1 impairs 
fusion of osteoclast precursors into multi-nuclear cells. It is also possible that 
decreased osteoclast activity, rather than changes in the numbers of osteoclasts, 
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was responsible for increased bone formation. lmmunostaining for specific 
osteoclast enzymes could provide insight into possible changes in osteoclast 
function. 
The increase in healing in the transgenic mice suggests that the 
ChemR23 receptor mediated anabolic action by RvE1 on bone-forming cells. 
Transgenic models of over-expression, such as that of L TB4 receptor BL T-1 
(511) or the human LXA4 receptor (hALX), were utilized for the functional 
evaluation of related pathways (512). In these mice, in the transgenic construct 
the ChemR23 sequence was linked to a CD11 b promoter (2) . CD11 b/CD18, 
also named macrophage antigen 1 (MAC-1) is an integrin expressed only in 
myeloid cells. Therefore, hChemR23 expression in these mice is limited to 
myeloid cells. 
The function of RvE1 in bone healing must be discussed in the context of 
other mediators known to be involved in this process. PGE2 is a lipid mediator 
with complex functions and was found to be essential in bone repair (73-75). 
Fracture healing was found to be delayed in COX2-deficient mice relative to 
COX1 deficient mice or wildtypes (75) . PGE2 and COX2 were found to be 
increased in fracture regions (79, 80) . Mechanical stress, which is necessary for 
functional bone remodeling after fracture healing, is mediated by PGE2 and 
COX2 (81-83). In contrast, studies in osteoporotic animals (389, 390) and in 
humans (391-393) found that PGE2 stimulates bone resorption. 
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Leukotrienes are lipid mediators derived from arachidonic acid. 
Compared to prostanoids, little is known about the effects of leukotrienes on 
bone. Leukotriene B4 (L TB4) stimulates the BL T-1 receptor, causing bone 
resorption in vitro in organ cultures of neonatal mouse calvariae (513). L TB4 
production is stimulated in inflammatory bone resorptive diseases such as 
rheumatoid arthritis (514-516), osteoarthritis (517, 518) and periodontitis (400, 
519). L TB4 receptor antagonists have been found effective for treatment of 
rheumatoid arthritis (520-522). L TB4 inhibits cell proliferation in normal 
osteoblastic rat calvaria cells in a dose-dependent manner and it has biphasic 
effects in human osteoblast-like osteosarcoma cell lines Saos-2 and G292 (523) . 
Leukotrienes are produced by lipoxygenases, enzymes that also catalyze 
the formation of lipoxins and resolvins. Similar to prostaglandins and 
leukotrienes, lipoxins are lipid mediators derived from arachidonic acid. Lipoxins, 
however, are pro-resolving molecules that have been shown to regulate 
neutrophil responses in inflammation in vivo (511, 524-528). Interestingly, similar 
to resolvins, in P.gingivalis-induced periodontal disease in rabbits, lipoxin ~ 
inhibited bone loss and connective tissue destruction (529) . Reduced bone loss 
and decreased local inflammation were obtained in transgenic rabbits 
overexpressing 15-LO type I, the enzyme that produces lipoxins (530). 
It would be of interest to collect additional information from the histology 
sections. lmmunostaining should be performed to reveal the presence of 
macrophages. Experiments can be performed to test the result of macrophage 
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depletion on calvaria healing. In a mouse model of healing of long bone, 
Alexander at al. showed that macrophage depletion using macrophage Fas-
induced apoptosis (Mafia) transgenic mice or clodronate liposomes inhibits bone 
mineralization and secretion of collagen (469). Based on the results of healing of 
the craniotomy defect in the transgenic mice, it was concluded that myeloid cells 
may be the source of the enhanced healing. Therefore osteal macrophages 
were initially the focus of the in vitro experiments. 
After validating the monocyte-macrophage phenotype and expression of 
ChemR23, experiments were designed to test the action of RvE1 in a co-culture 
model of macrophages and osteoblasts. Studies showed that depletion of 
macrophages results in a decrease of both OCN mRNA expression and 
extracellular matrix mineralization (343). The hypothesis was that RvE1 would 
induce alterations in macrophage production of cytokines, which would likewise 
induce osteoblasts to increase their production of mineralized matrix. PGE2 
decreased the calcium content of the macrophage-osteoblast co-cultures. RvE1 , 
which was expected to rescue the decrease in calcium induced by PGE2 , 
however, did not. 
The method of osteal macrophage purification determines the population 
of cells studied. Chang et al. purified macrophages from calvarial extracts using 
antibodies for F4/80 and found that mineralization was increased in macrophage-
osteoblast cultures relative to cultures from which macrophages had been 
eliminated (343). In the experiments detailed above, co-culture of macrophages 
167 
with osteoblasts did not induce changes in mineralization. It is likely that the 
macrophage populations obtained in the experiments detailed above were 
different, as they were isolated from bone marrow and were cultured in presence 
of M-CSF. It is also possible that the method used to analyze the experiment, 
i.e. calcium assay, lacked the sensitivity to detect differences among the groups. 
With pro-inflammatory stimulation, macrophages respond to PGE2 by 
secreting IL-6 in cell culture supernatants. Levels of other cytokines were not 
found to be altered by stimulation with PGE2. It is possible that these bone 
marrow macrophages require activation with a different type of ligand (i.e. 
bacterial) or multiple ligands. After using several sources of osteoblasts and 
varying experimental conditions, the conclusion that RvE1 treatment did not have 
an impact on macrophage-mediated stimulation of osteoblasts. 
The next experiments focused on osteoblasts as target cells for RvE1. 
The MC3T3 cell model facilitates study of the developmental sequence of 
osteoblast precursors. Malignant osteoblast cell lines are used in alternative 
osteoblast culture models. Those cell lines were not ideal for our project due to 
their unrepressed replicative activity and failure to display normal coupling of 
differentiation and growth arrest (531 ). MC3T3 are a phenotypically 
heterogeneous cell line, and multiple subclones have been characterized (474) . 
We chose to use the MC3T3-E1 subclone 4 due to its high levels of osteoblast 
differentiation after stimulation with AA and BGP (248). In order to be consistent 
with the calvaria healing experiments, and in order to provide a homogeneous 
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population of osteoblasts, cells isolated from neonatal calvaria were also used to 
test the action of RvE1 ;in addition to MC3T3. 
While the expression of ChemR23 was previously shown in developing 
osteoblasts, the function of ChemR23 in response to RvE1 was not anticipated 
based upon the transgenic mouse experiments. ChemR23 mRNA was found to 
be expressed both in osteoblast precursors and in differentiated calvaria 
osteoblast cultures (Fig. 13). In addition, the ChemR23 receptor was imaged by 
immunofluorescence in calvaria osteoblasts at different stages of differentiation 
(Fig. 14, 15). The significance of these results was to show that osteoblasts 
have the potential of responding to RvE1. 
Treatment of bone marrow macrophages with PGE2 resulted in secretion 
of IL-6. IL-6 is a cytokine produced by a variety of cells such as macrophages, 
fibroblasts, osteoblasts, and endothelial cells (532). IL-6 induces osteoclast 
formation and bone resorption (533). In addition to its direct action on 
osteoclasts, IL-6 decreases bone formation in vitro (438) and inhibits osteocalcin 
expression in osteoblasts (437). IL-6 stimulated osteoclastogenesis in co-
cultures of osteoblasts and osteoclasts (534, 535) , implicating direct IL-6 binding 
to osteoblasts as the pro-inflammatory stimulus leading to bone resorption. 
The balance between RANKL and OPG is critical for regulation of bone 
remodeling (536, 537) . In previous studies, IL-6 was not found to impact RANKL 
production (441 ). The observations in Aim 3 in osteoblasts agree with these 
studies. IL-6, however, significantly inhibited the secretion of OPG in calvaria 
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(Fig. 30) and bone marrow osteoblasts (Fig. 28), in agreement with previous 
studies, in which IL-6 was found to indirectly stimulate osteoclast formation 
through PGE2 by decreasing OPG (441 ). 
Co-stimulation with RvE1 blocked the decrease in OPG. More 
experiments are needed to establish if this inhibition only targets IL-6 signaling or 
whether IL-6 synthesis and secretion are also altered, which was not addressed. 
In previous studies, COX-2 inhibitors were shown to decrease IL-6 expression 
suggesting that IL-6 mediates the action of PGE2 on osteoclastogenesis (538). 
Overall , RvE1 was able to increase the ratio between OPG and RANKL, 
suggesting a negative action on bone resorption. 
In vivo, RvE1 increased bone formation in a craniotomy model of bone 
formation, suggesting an induction of increased number and/or function of 
macrophages and/or osteoblasts. The numbers of osteoclasts at the 14 day time 
point were low, and no differences in osteoclast numbers were found with RvE1 
treatment. Osteoclast numbers and activity are predicted to be increased during 
the remodeling step of repair. Thus it would be of interest to monitor osteoclast 
numbers at multiple time points after osteotomy in order to find a cellular 
correlate of the decreased RANKL:OPG ratio observed in vitro. 
RvE1 signaling pathways were targeted next. The Akt and MAPK 
pathways were previously shown to be activated in response to RvE 1 in 
leukocytes (1 00). Our results revealed that upon RvE1 stimulation there is an 
upregulation in phosphorylation of rpS6, a ribosomal enzyme that functions as 
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part of the Akt pathway. Blocking the ChemR23 receptor blocked 
phosphorylation of rpS6 demonstrating the specificity of the receptor for RvE 1 
action (Fig. 27). In our experiments, 'rapamycin blocked rpS6 phosphorylation, 
which demonstrated specific signaling of RvE1 via mTOR stimulation. 
rpS6 regulates production of ribosomal proteins and elongation factors 
necessary for translation (497, 498). The C terminus sequence is conserved 
. among several species, and is RRRLSSLRASTSKSESSQK249 . The 
phosphorylation sites have been mapped to Se~35 , Se~36 , Se~40 , Se~44 , and 
Se~47 (501 , 539). Se~36 was found to be the primary phosphorylation site (502). 
rpS6 has been shown to be directly involved, through its phosphorylation, in 
controlling cell size (540). In MC3T3 cells, rpS6 is expressed during the 
proliferation period and decreases after day 10 of differentiation (236) . 
In the bone marrow osteoblast experiments, it was hypothesized that 
RvE1 may increase the differentiation of osteoblasts. Osteoblasts were 
differentiated in presence of AA and BGP, and stimulated with TNF-a or PGE2. 
RvE1 did not alter the reduction in bone marker expression induced by the pro-
inflammatory factors TN F-a or PGE2 . From these experiments, it was concluded 
that RvE1 acts on differentiated osteoblasts. 
In a recent study, knockdown of ChemR23 expression in bone marrow 
stromal cells (BMSCs) resulted in reduced adipocyte differentiation and 
increased expression of osteoblast markers and mineralization (165). The 
knockdown of a particular gene invariably impacts multiple cells and may have 
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indirect as well as direct actions. In these experiments, the data suggest that 
RvE1 does not act on osteoblast differentiation through ChemR23 expressed on 
BMSC of osteoblast lineage and likely acts 'through accessory cells. 
The transcription factor NF-kB has an important role in inflammation and 
immune response (486-490). RvE1 has been shown to inhibit NF-kB induction 
by TN F-a in ChemR23-transfected cells (1 00). NF-kB has been shown to have 
an inhibitory action on bone formation (492) . In our experiments, stimulation with 
TN F-a induced an increase in NF-kB luciferase reporter activity (Fig . 24). RvE1 , 
however, did not decrease TN F-a induction of NF-kB. Further studies are 
necessary to elucidate the interaction between the IL-6, OPG and RvE1 
pathways. 
Resolution of inflammation is an active process, whereby the inflammatory 
response is terminated and health is restored. This process is relevant to 
osteoimmunology since the initiation of bone healing is mainly an inflammatory 
process, and as such must be tightly regulated. Many drugs are currently in use 
for the treatment of inflammatory conditions. Although some of these drugs are 
clinically effective, at least in the short term , they may also cause severe side 
effects. Inflammatory conditions such as joint, bowel and pulmonary diseases, 
as well as autoimmune disorders and the prevention of transplant rejection , are 
often treated with glucocorticoids. In addition to their anti-inflammatory 
properties, glucocorticoids promote resolution by enhancing macrophage uptake 
of apoptotic PMN (541 ). These drugs, however, have deleterious systemic and 
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skeletal effects. Osteoporosis is the most common debilitating complication of 
glucocorticoid use (541, 542), and it is caused not only by decreased bone 
formation (543) but also by increased bone resorption (544) . Therefore, in an 
effort to promote healing without inducing debilitating and even life-threatening 
side effects, it is essential to develop novel therapeutic strategies for treatment of 
inflammatory conditions. 
Putting together the results of the experiments and what is reported in the 
literature, a model for the actions of RvE1 in bone regeneration after 
inflammatory bone loss is proposed. It is clear from the literature that activation 
of resolution of inflammation pathways removes the stimuli for tissue destruction 
mediated by chronic inflammation including a variety of catabolic proinflammatory 
cytokines through the modulation of cell phenotype. 
The hypothesis of these experiments, supported by earlier work in the lab 
on osteoclast responses to resolvins, is that resolution of inflammation by itself is 
not sufficient to account for new bone formation and regeneration of the 
periodontal organ. My investigations focused on how RvE1 might impact 
osteoblast function. RvE1 directly signals osteoblasts through the receptor 
ChemR23 expressed on its surface. The data suggest that ChemR23 in 
osteoblasts signals via an Akt-mTOR-rpS6 pathway. The action of RvE1 on 
osteoblast function is mediated , in part, by a reversal of OPG inhibition induced 
by inflammation that restores a RANKL-OPG ratio that inhibits osteoclasts and 
favors bone formation . 
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Previous work by Dr. Herrera in our lab demonstrated that RvE1 directly 
inhibits fusion of monocytes into giant cells through action on the BL T-1 receptor. 
RvE1 does not inhibit differentiation of monocytes into mononuclear osteoclasts. 
Dr. Min Zhu demonstrated that the impaired fusion in response to RvE1 occurs 
by inhibition of the fusion protein DC-STAMP through NFATc1. Taken together, 
these data suggest that RvE1 receptors are expressed on bone cells and that 
there is direct impact of innate immune mediators on both major bone cell types 
in addition to cells traditionally associated with innate immunity such as myeloid 
and lymphoid cells. 
While this line of investigation is exciting from the perspective of 
osteoimmunology, there are still many questions to be answered in future 
studies. It is still unclear how RvE1 interferes with IL-6 inhibition of OPG. 
Investigation of the IL-6 signaling pathway leading to OPG secretion and how 
rpS6 phosphorylation acts on this pathway is necessary. In addition, the 
reported function of rpS6 is in proliferation pathways; the impact of RvE 1 on 
osteoblast proliferation has not been studied. 
On a more global scale, RvE1 is a single resolution agonist among many, 
such as lipoxins, maresins, and resolvins derived from DHA. There is a 
suggestion in the resolution of inflammation literature that exogenous addition of 
one resolution agonist promotes the production of others. Characterization of the 
interaction among all resolution circuits in bone is completely unexplored, as is 
the impact of resolution of inflammation on bone regeneration. 
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6 Summary 
The field of osteoimmunology explores the interaction among bone and 
components of the immune system. The goal of our project was to investigate 
one aspect of this interaction, specifically the action of RvE1 on osteoblasts. 
We have shown that local injections of RvE1 increase bone formation in 
vivo in a calvaria defect model in mice. This experiment supports the hypothesis 
that RvE1 is beneficial for bone regeneration. 
Osteal macrophages, which are immune cells resident in the bone, were 
found to express IL-6 in response to PGE2 stimulation. IL-6 is a cytokine that 
causes osteoclast differentiation directly and indirectly through osteoblasts. 
ChemR23, a GPCR receptor known to mediate RvE1 actions, is 
expressed in osteoblasts. RvE1 increases the phosphorylation of rpS6, a protein 
that functions in the Akt pathway and is part of the 40S ribosomal subunit. This 
action on rpS6 is mediated through ChemR23 and mTOR, as blocking of either 
inhibits the rpS6 phosphorylation. 
RvE1 blocks an IL-6-induced decrease in secreted OPG, without altering 
RANKL. The resulting decrease in RANKL/OPG may cause a decrease in 
osteoclast differentiation. 
RvE1 is known to enhance resolution of inflammation in other tissues. 
Our in vivo results indicate that RvE1 exerts an anabolic action on osteoblasts in 
a calvarial model of mice injected with RvE 1. The series of experiments 
described investigated the mechanism of this action. RvE1 may have positive 
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actions on bone remodeling by blocking the action of IL-6 and decreasing the 
ratio of RANKL to OPG. The specific mechanism by which RvE1 blocks IL-6 
invites additional study. 
In conclusion, the response of osteoblasts to RvE1, a mediator of 
resolution, suggests an innate immune function of these cells. Our experiments 
show that RvE1 may be beneficial in bone remodeling. It is possible that in the 
future, RvE 1-based therapies may evolve to provide bone-sparing anti-
inflammatory treatment for patients at risk of lytic bone diseases including 
osteoporosis, arthritis and periodontal diseases. 
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